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ABSTRACT 
Magnetic resonance spectroscopic imaging (MRSI) is a valuable technique for 
assessing the in vivo spatial profiles of metabolites like N-acetylaspartate (NAA), 
creatine, choline, and lactate. Changes in metabolite concentrations can help identify 
tissue heterogeneity, providing prognostic and diagnostic information to the clinician. 
The increased uptake of glucose by solid tumors as compared to normal tissues and its 
conversion to lactate can be exploited for tumor diagnostics, anti-cancer therapy, and in 
the detection of metastasis. Lactate levels in cancer cells are suggestive of altered 
metabolism, tumor recurrence, and poor outcome. A dedicated technique like MRSI 
could contribute to an improved assessment of metabolic abnormalities in the clinical 
setting, and introduce the possibility of employing non-invasive lactate imaging as a 
powerful prognostic marker. 
However, the long acquisition time in MRSI is a deterrent to its inclusion in 
clinical protocols due to associated costs, patient discomfort (especially in pediatric 
patients under anesthesia), and higher susceptibility to motion artifacts. Acceleration 
strategies like compressed sensing (CS) permit faithful reconstructions even when the k-
space is undersampled well below the Nyquist limit. CS is apt for MRSI as spectroscopic 
data are inherently sparse in multiple dimensions of space and frequency in an 
appropriate transform domain, for e.g. the wavelet domain. The objective of this research 
was three-fold: firstly on the preclinical front, to prospectively speed-up spectrally-edited 
MRSI using CS for rapid mapping of lactate and capture associated changes in response 
to therapy. Secondly, to retrospectively evaluate CS-MRSI in pediatric patients scanned 
for various brain-related concerns. Thirdly, to implement prospective CS-MRSI 
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acquisitions on a clinical magnetic resonance imaging (MRI) scanner for fast 
spectroscopic imaging studies. Both phantom and in vivo results demonstrated a 
reduction in the scan time by up to 80%, with the accelerated CS-MRSI reconstructions 
maintaining high spectral fidelity and statistically insignificant errors as compared to the 
fully sampled reference dataset. Optimization of CS parameters involved identifying an 
optimal sampling mask for CS-MRSI at each acceleration factor. It is envisioned that 
time-efficient MRSI realized with optimized CS acceleration would facilitate the clinical 
acceptance of routine MRSI exams for a quantitative mapping of important biomarkers. 
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CHAPTER 1 
MAGNETIC RESONANCE SPECTROSCOPIC IMAGING 
 
1.1   Introduction 
Magnetic resonance spectroscopic imaging (MRSI, also known as chemical shift 
imaging or CSI), which was first introduced by Brown et al [1] and later developed 
further by Maudsley et al [2], is a key non-invasive imaging technique for measuring and 
monitoring metabolic profiles in vivo in conjunction with other anatomical and functional 
sequences [3, 4]. MRSI can identify and quantify the metabolic differences between 
healthy and diseased tissue, thus, providing prognostic and diagnostic information to the 
clinician that could improve treatment strategies. Proton (1H) MR spectroscopy has been 
extensively employed to probe tissue metabolism in tumor models of the brain, breast and 
prostate over the last couple of decades [5-14]. For example, increased levels of choline 
and reduced NAA (N-acetyl aspartate) are typically seen in brain tumors [7, 8, 12], while 
malignant breast lesions express raised concentrations of total choline [5, 6, 9, 10]. 
Cancers of the prostate are associated with decreased citrate levels along with an increase 
in choline, phosphocholine, lactate, and phosphoethanoamine [11, 13, 14].  
MRSI can also establish direct correlations with anatomical imaging and can be 
linked to physiological measurements such as perfusion and diffusion imaging [15]. 
While in vivo MRSI has been demonstrated with other nuclei, 1H MRSI is the 
spectroscopic imaging technique of choice for imaging in the clinic because of greater 
hydrogen abundance and commercially available equipment, as compared to 13C, 31P, and 
23Na MRSI. Nevertheless, these other nuclei are also very useful in investigating specific 
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metabolic processes [16-20]. Although MRSI can monitor clinically relevant 
biomolecules, its clinical use is limited by the extremely long acquisition time, limited 
spatial coverage, and low signal-to-noise ratio (SNR). 
 
1.2   Localization Techniques in MRS 
Localization methods in MR spectroscopy utilize reference anatomical images 
from MRI to define the desired volume of interest (VOI) for spatially selective 
acquisition of spectra [21]. Ideal MRS pulse sequences should acquire good quality 
spectra from within the VOI, with minimal interference from unwanted signals outside 
the desired volume. However, the in vivo detection and accurate quantification of 
metabolites is complicated by several factors such as the presence of huge resonances 
from water and lipid, low spectral resolution due to heterogeneity in the B0 field 
distribution, and low signal to noise ratio (SNR). MRS localization techniques in the 
clinic rely on the B0 gradients (phase encoding and slice selection) employed in MRI to 
achieve spatial selectivity, along with spatial saturation bands and signal cancellation 
procedures for effective outer volume suppression [21]. 
 
1.2.1 Single Voxel Spectroscopy 
In single voxel spectroscopy (SVS), the desired tissue VOI is defined by the 
gradient selection of three orthogonal planes or slices. A single spectrum is then acquired 
from the selected VOI. This localization along three dimensions can be achieved using 
the point resolved spectroscopy (PRESS) and stimulated echo acquisition mode 
(STEAM) pulse sequences. Both techniques use three frequency selective radio 
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frequency (RF) pulses to excite the volume of interest, as depicted in Figure 1.1. 
However, the timing diagram of the two sequences, along with the flip angles of the RF 
pulses and placement of the spoiler gradients are different, even though both share the 
principles of volume selection [21]. The two sequences also differ in the achievable SNR 
(SNRSTEAM = SNRPRESS/2), the minimum TE that can realized, water suppression, 
artifacts resulting from chemical shift, and sensitivity to motion. Additional chemical 
shift selective saturation (CHESS) pulses are employed to suppress the huge interfering 
signals from water and lipid.  
 
 
Figure 1.1 SVS localization sequences. (a) The PRESS MRS sequence timing diagram. 
Both the 90o excitation pulse and the two 180o refocusing pulses are slice-selective and 
are applied in orthogonal directions to achieve spatial localization.  (b) The STEAM 
sequence that uses three 90o slice-selective pulses for spatial localization. Reproduced 
from [22].  
 
SVS pulse sequences are currently employed in the clinic since a single averaged 
spectrum can be quickly acquired from the desired VOI, such as from a region containing 
a tumor. Depending on the selected sequence parameters such as the repetition time (TR), 
number of averages, and the volume size, the scan time can be as less as a few seconds to 
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acquire a quantitatively good spectrum. Furthermore, SVS is popular due to its ease of 
implementation and simplicity, better water suppression, more homogeneous B0 
shimming achievable on smaller voxels, lack of artifacts from voxel-to-voxel bleed, and 
immediate analysis and interpretation of the spectra. However, as only a single spectrum 
can be obtained at a time from the defined volume, multiple measurements might be 
necessary when evaluating several regions of the anatomy [21]. This limits the benefit of 
SVS in accessing voxel-to-voxel variations in metabolite concentrations in a single 
measurement. 
 
1.2.2 Chemical Shift Imaging 
CSI combines the features of both spectroscopy and imaging by acquiring 
multiple spectra from adjacent voxels in a single scan. There is no readout gradient 
applied in MRSI during data collection, and phase encoding gradients are applied in 
either one (1D), two (2D), or three (3D) directions to achieve spatial localization [21]. A 
three dimensional fast Fourier transform (FFT) is then applied to reconstruct the MRSI 
data. Following reconstruction, the acquired spectral data is post processed and displayed 
as spectra or metabolite maps overlaid on the anatomical reference image. Figure 1.2 
illustrates a conventional volume-selective 2D MRSI pulse sequence based on the PRESS 
excitation scheme, along with representative spectra and metabolite maps from a clinical 
MRSI dataset. The PRESS volume is excited using three slice-selective RF pulses and 
gradients Gx, Gy, and Gz. The second half of the echo produced at TE2 is sampled. A 3D 
(kx, ky, t) matrix is generated by applying phase encoding gradients along the x and y 
directions to spatially encode the echo. 
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Due to the availability of spectra from multiple contiguous voxels, MRSI aids the 
comparison of metabolic profiles from different types of tissues. For e.g. in cancer 
patients, spectra from normal and tumor tissue can be simultaneously acquired to 
evaluate heterogeneity in metabolite concentrations. Multiple voxels acquired from 
within the tumor region can also be used to assess whether there is any heterogeneity in 
metabolite distributions in the same lesion [21]. Multiple adjacent voxels can also be 
combined to replicate the shape of the tumor and subsequently combine the 
corresponding spectra.  
However, MRSI has its share of problems, the primary one being the long scan 
time even when acquiring a low resolution spectroscopic grid, for e.g. a 16 x 16 matrix 
with a TR of 1.5 s and one signal average would require a scan time of 6.4 minutes. A 
long TR > 1 s is required since most metabolites have long T1 recovery times. Multiple 
averages are often required in regions that are inherently SNR limited, causing a further 
increase in the acquisition time. Variations in magnetic susceptibility are encountered 
since a relatively large excitation volume is selected in MRSI, leading to non-uniform 
water suppression and poor shimming. This in turn affects the point spread function 
(PSF), giving rise to spectral contamination from the resulting voxel bleed that could give 
rise to errors in spectral interpretation [21]. Furthermore, the complete analysis of MRSI 
data requires several processing steps that might also vary between different data types 
[23]. A lack of standardization in MRSI acquisition protocols and non-availability of 
common processing and analysis tools for a simple and quick evaluation of metabolite 
concentrations makes this technique less appealing to the radiologist for routine clinical 
investigations.     
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Figure 1.2 Conventional MRSI data acquisition. (a) A PRESS-based volume selective 
2D MRSI pulse sequence. The second half of the second echo at time TE2 is sampled. 
The total acquisition time in 2D MRSI for a slice in the z direction would be Nx x Ny x 
Navg x TR, where, Nx and Ny are the number of phase encodes along the x and y 
directions, respectively, Navg is the number of signal averages, and TR is the repetition 
time of the pulse sequence. (b) Representative metabolite maps of the major brain 
metabolites NAA, creatine (Cr), choline (Cho), and lactate seen in a brain tumor patient 
with spectra from normal and tumor voxels.  
7 
 
1.3   Key Metabolites Observed in 1H MRS/MRSI 
1.3.1 N-acetylaspartate 
The methyl (CH3) group of N-acetylaspartate (NAA) gives rise to a prominent 
singlet at 2.01 ppm in the proton spectrum observed in MRS/MRSI. Three doublet-of-
doublets are also found centered at 2.49 ppm, 2.67 ppm, and 4.38 ppm (from the CH2 and 
CH groups), with a broad temperature-sensitive resonance at 7.82 ppm (from the 
exchangeable amide NH proton). NAA is found exclusively in the peripheral and central 
nervous systems, with different parts of the brain showing varied concentrations [4, 21, 
24]. Higher concentrations are found in gray matter (~8-11 mM) as compared to that 
found in white matter (~6-9 mM). NAA has been found to play an important role in (1) 
fatty acid and myelin synthesis, (2) osmoregulation, and (3) in being the break down 
product of the neurotransmitter NAAG. NAA does not play a vital role in the energy 
metabolism of glucose in the resting brain as evidenced by the slow NAA turnover 
observed in 13C NMR spectroscopy. The average concentration of NAA in the normal 
adult brain varies between 7.5 – 17.0 mM/L [4, 21, 24], while that in the rat brain is in the 
range of 4.5 – 9 mmol/L [4, 21, 24]. 
The NAA resonance is primarily viewed as a marker of neuronal density. 
Dynamic changes in NAA concentrations are suggestive of neuronal dysfunction as 
opposed to neuronal loss. Several brain disorders like stroke, temporal lobe epilepsy, 
multiple sclerosis, and hypoxic encephalopathy exhibit a decrease in NAA levels [25]. In 
multiple sclerosis, both visible lesions as well as normal appearing regions of while 
matter show reduced NAA concentration [26]. NAA loss is also observed in malignant 
brain tumors due to destruction of neurons, particularly in extra-axial meningiomas [25]. 
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Brain abscesses and secondary (metastatic) neoplasms may show reduced or completely 
absent signal from NAA [26]. In ischemia or hypoxia, NAA is used as a concentration 
maker, as the acute metabolic disturbances in these diseases do not significantly alter its 
concentration [24].    
 
1.3.2 Creatine 
The methyl and methylene protons of Cr and phosphorylated creatine (PCr) give 
rise to singlet resonances at 3.03 ppm and 3.93 ppm, respectively. Both glial and neuronal 
cells in the brain contain Cr and PCr. Creatine is mostly synthesized in the liver and 
kidneys. Total creatine (tCr), which is the sum of Cr and PCr, plays an important role in 
the energy metabolism of tissues, along with adenosine triphosphate (ATP) [4, 24]. PCr, 
in combination with creatine kinase, plays two major roles: (1) maintains constant ATP 
levels via the creatine kinase reaction, serving as an energy buffer, and (2) it functions as 
an energy shuttle by diffusing from energy producing regions like the mitochondria to 
energy consumption sites like the muscle and brain. The concentration of Cr and PCr in 
the normal human brain has been reported to be 4.5 – 6.0 mM and 4.0 – 5.5 mM, 
respectively [4, 24]. Lower levels are found in white matter (5.2 – 5.7 mM) as compared 
to that in gray matter (6.4 – 9.7 mM) [4, 24].  
TCr is frequently employed as an internal concentration reference as levels 
remain relatively constant in various diseases, with no changes being observed even with 
age. However, any internal concentration reference must be used with caution as regional 
and individual variations in concentration are likely. Chronic phases of various tumors 
and stoke have displayed a decrease in Cr levels. Increased metabolic activity in certain 
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high-grade gliomas may reduce the total creatine concentration [25]. As Cr is not 
generated in the brain, other diseases like renal diseases may affect creatine levels in the 
brain [25]. Reduced or absent creatine signal has been observed in various conditions like 
seizures, brain abscesses, AIDS, autism, and mental retardation [27]. Prostate cancers 
have shown higher creatine levels as compared to normal prostate tissue [28].   
 
1.3.3 Choline 
The methyl protons of choline-containing compounds give rise to a prominent 
singlet at 3.2 ppm in the 1H MRS spectrum. This peak is the signal from ‘total choline’ 
(tCho), which contains contributions from free choline, phosphorylcholine (PC), and 
glycerophosphorylcholine (GPC). The peak at 3.2 ppm has a significant contribution 
from betaine in tissues present outside the central nervous system (CNS). In the normal 
adult human brain, the concentration of total choline is approximately 1 – 2 mM, with a 
non-uniform distribution in the brain [24]. Choline-containing compounds are reflective 
of membrane turnover, as they are involved in the phospholipid synthesis and 
degradation pathways [24].  
Fluctuations in the levels of the tCho peak have been seen in various diseases. 
Increased choline concentration has been observed in various brain, breast, and prostate 
cancers, in Alzheimer’s disease, and in demyelinating autoimmune diseases like multiple 
sclerosis [24]. On the other hand, reduced choline signal has been detected in stroke and 
liver disease [24]. Multiple contributions to the observed total choline signal tend to 
complicate an accurate interpretation of changes in tCho. In malignant tumors and 
(primary and secondary/metastatic) neoplasms, increased cellularity causes an increase in 
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the total choline concentration [25]. Various factors at the cellular level contribute to an 
elevated choline signal, such as destruction of normal cells or increased cell membrane 
turnover due to tumor growth. The choline signal has been found to be absent in brain 
abscesses, while a very prominent choline peak has been reported in the lymphoma in 
AIDS [25]. 
 
 
Figure 1.3 Chemical structure of major metabolites observed in the 1H MRS/MRSI 
spectrum [29]. 
 
1.3.4 Lactate 
The three equivalent methyl (CH3) protons of the lactate molecule produce a 
doublet at 1.31 ppm, while the single methine (CH) group gives rise to a quartet at 4.10 
ppm. Large resonances from the lipid molecules tend to overlap with the lactate doublet, 
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particularly in regions with poor localization. Under such circumstances, specialized 
spectral editing techniques need to be employed for improved detection of the lactate 
peak [24]. Lactate is present in very low concentrations (~0.5 ppm) in normal resting 
tissues and is the end-product of anaerobic glycolysis. According to the astroglial-
neuronal lactate shuttle (ANLS) hypothesis, neurotransmitter cycling and metabolism is 
linked to astroglial glucose uptake and metabolism via the lactate molecule [24].  
High lactate concentrations have been found in various diseases like brain 
abscesses, brain ischemia, primary and secondary neoplasms, seizures, and in regions of 
acute inflammation, as signified by macrophage accumulation [25]. In all the above 
mentioned conditions, a failure in the aerobic oxidation process leads to an increased 
uptake and conversion of glucose to lactate by the Warburg effect, leading to increased 
lactate accumulation [30]. Furthermore, poor washout mechanisms in cystic and necrotic 
tumors lead to higher lactate levels in malignant lesions. Functional activation and 
hyperventilation in the human brain has also been found to cause a transient increase in 
the lactate signal [24]. 
 
1.3.5 Other Important Metabolites 
A detailed description of NAA, creatine, choline, and lactate was provided in the 
previous sections as these metabolites were observed and quantified in the studies 
presented in Chapters 3, 4, and 5 of this dissertation. Other metabolites that are key 
biomarkers in various diseases are also observed in the MRS spectrum, such as alanine, 
citrate, γ-Aminobutyric Acid (GABA), glutamate, glutamine, glycine, and myo-Inositol. 
An increase in alanine levels has been found in ischemia and in meninigiomas [24], while 
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in prostate cancer, increased oxidation due to a drop in zinc levels leads to a significant 
decrease in the citrate concentration [24]. Altered concentrations of GABA are have been 
detected in several psychiatric and neurological disorders, such as depression and 
epilepsy [24]. Both glutamate and glutamine play an important role in the 
neurotransmitter cycle, while glycine functions as an antioxidant and inhibitory 
neurotransmitter [24]. Variations in myo-Inositol levels have been detected in brain 
injury and Alzheimer’s disease, with osmotic regulation being another role played by this 
metabolite in the kidney [24]. Figure 1.4 shows the metabolites that can be detected in the 
1H MRS spectrum. 
 
Figure 1.4 Metabolites seen in the 1H MRS spectrum in the (a) 0.75 – 2.85 ppm range, 
and (b) 2.85 – 4.45 ppm range. Reproduced from [29].  
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1.4   Data Processing in MRS/MRSI 
The acquired MRSI data are processed and analyzed in order to determine 
absolute/relative metabolite concentrations, and to present the metabolic information in 
an easily interpretable format to the radiologist. Various processing steps that can be 
applied to manipulate the MRSI data in either the time or frequency domain are briefly 
outlined below [21]. 
(1) DC Offset Correction 
A DC offset present in the FID signal will produce a spike at zero frequency (0 
Hz/ppm) in the corresponding spectrum. The offset is estimated from the baseline of the 
FID data and subtracted before applying the Fourier transform to eliminate the spike.  
(2) Zero-filling 
The FID can be zero-filled in order to improve the spectral resolution, thus, 
facilitating a better discrimination of various spectral features, like peak positions and 
amplitudes. Zero-filling should be applied with caution, as this might lead to baseline 
artifacts in the resulting spectrum when the FID has not completely decayed to the noise 
floor.   
(3) Apodization 
The FID signal is usually multiplied with a filter function to improve the SNR and 
reduce any truncation artifacts. For e.g. a decaying exponential filter like the Gaussian 
filter suppresses the noise at the end of the FID. This helps in improving the SNR while 
causing a broadening of the spectral peaks (which depends on the line broadening 
constant of the applied filter). Step-like signal discontinuities are also eliminated as the 
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filter smooths the FID signal decay to zero, removing sinc-like side lobes in the resulting 
spectrum. 
(4) Phase Correction 
Prior to quantification, the real and imaginary components of the complex 
spectrum need to be accurately determined from the pure absorption and dispersion 
modes. A constant or zero-order phase correction φ0 is applied when all signal 
components experience the same phase shift, for e.g. if the transmitted and received RF 
signals have a fixed phase difference. A linear or first-order phase correction φ1 is 
required when various signal components experience different phase shifts. Both φ0 and 
φ1 are varied independently to get the best separation between the absorption and 
dispersion modes. 
(5) Baseline Correction 
The baseline of a MR spectrum should be flat and free of distortions for accurate 
estimation of peak areas. Baseline distortions are more pronounced in spectra obtained at 
short TE, especially when the residual water signal is not properly subtracted during post 
processing. Other distortions are introduced by immobile nuclei such as macromolecules, 
which give rise to broad plateaus in the MRS spectrum. Polynomial or cubic-spline based 
fitting is used to approximate and correct for any distortions in the baseline.  
(6) Removal of Residual Water 
A significant residual water peak remains in the spectrum in regions where the 
localization and OVS suppression was poor, for e.g. in the peripheral regions of the brain 
where the magnetic field may not be homogeneous. This residual water peak has to be 
eliminated prior to metabolite fitting and quantification. Techniques like the singular 
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value decomposition (SVD) and the Hankel-Lanczos variant (HLSVD) [31] allow 
reliable automatic suppression of any residual water, with little to no user input required. 
(7) Spectral Fitting & Quantification 
The final step in the processing and analysis of MRS/MRSI data involves fitting 
the various peaks of interest in the spectrum to known line shape functions such as the 
Gaussian (more common for solids), Lorentzian, or a combination of two or more 
functions [21]. Spectral components can be estimated using various quantification 
algorithms such as AMARES (Advanced Method for Accurate, Robust and Efficient 
Spectral fitting) [32], HLSVD [31], HTLS [33], and QUEST (QUantitation based on 
QUantum ESTimation) [34, 35]. A priori information like the frequency range, full width 
at half maximum (FWHM), peak positions and amplitudes can be specified to obtain a 
good peak fit. The best fit between the measured and theoretical curves is then 
determined using an iterative curve fitting algorithm. Curve fitting techniques can be 
applied in either the frequency or time domain. After post processing, results are 
displayed either as an individual spectrum (in case of SVS), or as individual metabolite 
maps overlaid/co-registered on the anatomical reference image in MRSI. 
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CHAPTER 2 
FAST DATA ACQUISITION STRATEGIES IN MRSI 
 
Fast scan strategies could potentially facilitate increased adoption of MRSI into 
routine clinical protocols with minimal addition to the current acquisition times. Not 
surprisingly, a lot of effort has been devoted to the development of faster MRSI 
techniques that aim to capture the same amount and quality of information as 
conventional MRSI in greatly reduced time. This chapter examines the current techniques 
and advances in high-speed MRSI in 2- and 3-dimensions and their applications. Since 
encoding of position in conventional MRSI itself is an extension of that in MRI, most of 
these acceleration techniques are not MRSI-specific. All discussed acceleration 
approaches have initially been applied and tested in MRI before their adoption in MRSI. 
However, each acceleration technique has been suitably modified to accurately capture 
the challenges and nuances of spectroscopic imaging. The advantages and limitations of 
each state-of-the-art technique have been reviewed in detail, concluding with a note on 
future directions and challenges in the field of fast spectroscopic imaging. 
 
2.1   Conventional MRSI 
A PRESS-based volume selective conventional 2D MRSI sequence has 
previously been described in Chapter 1. The data acquisition process in conventional 
MRSI is tedious, which is a deterrent for its integration into current clinical protocols. A 
large number of phase encoding gradients need to be played out to sample all points in k-
space, leading to long scan times. Parameters like the TR of the MRSI pulse sequence, 
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size of the spectroscopic imaging grid, and the number of signal averages required to 
achieve good SNR determine the total acquisition time. For e.g. for a TR of 1.5 s and one 
signal average, the clinical acquisition of a 16 x 16 x 2048 spectroscopic imaging grid 
would require a scan time of 6 min 24 s. While on the other hand, one can realize a 
shorter scan time in MRI by applying frequency encoding along one direction, with phase 
encoding along the remaining dimensions.  
There is often a further increase in the scan time due to the need for higher signal 
averaging to ensure acceptable SNR and/or when high resolution MRSI data are 
acquired. 3D MRSI datasets cannot be acquired in patients, especially in the pediatric 
setting, due to the prohibitive scan time. E.g. the acquisition of a 16 x 16 x 16 spatial 
matrix would require a scan time of ~ 1.14 hours, considering one signal average and a 
TR of 1 s. The total imaging time is further increased as it is also necessary to collect 
reference anatomical information in every study. Another limitation to be considered in 
MRSI is the inherent low SNR, which arises from the MR visible metabolites having low 
concentrations in the range of <0.1 to 16.6 mM [29], as compared to 55 M of water in the 
human body. One can potentially lower the resolution and utilize the time gained to 
increase the SNR. This would, however, cause a volume averaging of the voxels and 
potentially lower the contrast to noise ratio (CNR) of the target metabolite with respect to 
the other metabolites. On the other hand, higher averages at the same resolution would 
lead to a further increase in the scan time. 
The above discussed limitations do not make conventional MRSI a feasible option 
to the clinician for regular in vivo investigations. Increased volume coverage at 
acceptable SNR and imaging speed are critical to the incorporation of MRSI in the clinic. 
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To this end, numerous fast imaging strategies that have been developed to achieve 
acceleration in MRI have been accordingly modified and applied to MRSI to shorten the 
scan time. Acceleration techniques will facilitate the evaluation of serial changes in 
metabolite distributions and heterogeneity in spatial profiles in a clinically viable time 
frame [15]. Such innovative pulse sequences will not only reduce the scan time, but will 
ensure best use of the available magnetization to simultaneously achieve/preserve good 
SNR and spatial resolution. Parallel advances in the design of efficient gradients, 
multichannel RF coils, sophisticated reconstruction algorithms and post processing 
routines, and high field scanners will make a significant contribution to realizing these 
goals.  
 
2.2   Fast MRSI with More Efficient K-space Traversal 
A major approach to achieve acceleration in MRSI data acquisition is to traverse 
the k-space in a more time efficient manner i.e. effectively cover more k-space locations 
within the chosen TR. This includes novel k-space sampling schemes like non-Cartesian 
trajectories (spiral, radial, rosette, etc) and pulse sequences that acquire multiple lines of 
k-space within the same TR. Techniques that fall under this category usually gain speed 
at the cost of SNR loss and resulting coherent artifacts.  
 
2.2.1 Turbo MRSI 
One of the first acceleration techniques to accelerate MRSI data, particularly in 
the brain [36, 37], was multi-echo imaging. Duyn et al developed a multi-echo, multi-
slice MRSI technique that enabled the acquisition of multiple spin echoes within the 
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same TR [36]. In conventional spectroscopic imaging, there is pronounced attenuation of 
the fat and water resonances arising from T2 decay, as a single spin echo signal is 
commonly sampled at long echo time (TE). The metabolites of interest, such as NAA, 
creatine, and choline experience greater signal decay from intra voxel susceptibility 
effects as compared to T2 decay. Thus, multiple spin echoes were acquired in the same 
TR to increase the efficiency of data collection, leading to a decrease in the scan time. An 
echo train length of 4 was used to achieve a 4X decrease in the acquisition time as 
compared to the single echo technique [36]. A fast spin echo based spectroscopic imaging 
sequence is illustrated in Figure 2.1.  
 
Figure 2.1 A turbo or fast spin echo spectroscopic imaging sequence. This sequence 
generates and acquires slice-selective spin echoes at echo times TE1, TE2, …,TEX, in 
intervals between the 180o RF pulses. Gx, Gy, and Gz depict the gradient channels. Phase 
encoding gradients encode each individual echo in the acquisition interval. Crusher 
gradients (indicated by the diagonally shaded gradient pulses) around the 180o pulses 
suppress any unwanted signals. Any other unwanted coherences are suppressed with the 
help of phase encoding rewinders. Gradient pulses depicted by the solid gray boxes 
represent slice-selective gradients. Additional outer volume suppression (OVS) and water 
suppression modules can be added before the 90o pulse. Adapted from [36]. 
 
20 
 
However, this technique does have several limitations. The data acquisition 
readout for spectroscopic imaging needs to be of the order of 0.3–1 s to maintain 
reasonable spectral resolution, and significant T2 decay would have already occurred by 
the time the subsequent echoes are encountered [37]. Consequently, metabolites with 
short T2 cannot be observed using this technique. This may force one to accept limited 
spectral resolution due to fewer echoes and smaller acquisition windows to gain speed. 
There is also considerable T2 weighting of different echoes, and metabolites like lactate 
need to be imaged carefully taking into account the fact that the choice of TE modulates 
the signal appearance of these metabolites [37]. Also, for long echo train lengths, the 
minimum TR often needs to be increased to accommodate the long readout window 
required, which tends to offset the time gained in multi-echo encoding. 
Other related multi-echo based fast MRSI techniques include the spectroscopic 
ultrafast low-angle rapid acquisition with relaxation enhancement (UFLARE) [38, 39], 
and the spectroscopic gradient and spin echo (GRASE) [40] imaging techniques (Figure 
2.2). Spectroscopic UFLARE acquires “slices” of  k-space by measuring all data points in 
the kx-ky plane at a given value kω after each signal excitation, i.e. within the TR using 
the fast imaging method UFLARE [41]. There are two different ways to encode the 
chemical shift.  In the first approach, the beginning of the imaging sequence is shifted 
with respect to the RF excitation in subsequent measurements. Alternately, the time 
interval between the 90° excitation pulse and the imaging sequence is kept constant and 
the position of a refocusing 180° pulse, applied within that interval, is incremented to 
encode the chemical shift. In spectroscopic GRASE, after each signal excitation, all data 
points from NGE gradient echoes kx-ky slices are acquired at different kω-values by using a 
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GRASE imaging sequence [42]. The delay between consecutive gradient echoes, which 
are measured with uniform phase encoding between consecutive refocusing pulses, is the 
inverse of the spectral width (SW). A refocusing 180° pulse, which is applied within a 
constant delay between excitation and the GRASE sequence, is shifted for subsequent 
measurements by an increment NGE/(2*SW) to cover the whole kω-kx-ky-space. 
 
 
Figure 2.2 Spectroscopic (a) U-Flare and (b) GRASE imaging pulse sequences with a 
pre-saturation period (A), excitation and evolution (B), an optional localization period 
(C), and readout (D). Spoiler gradients are denoted by diagonally shaded gradient pulses, 
while solid gray and white boxes depict slice-selective and read-out gradients, 
respectively. The alternate phase-encoding scheme was employed for signal acquisition. 
Spectroscopic GRASE enables effective homonuclear decoupling, while achieving a 
lower minimum acquisition time (Tmin) as compared to the spectroscopic U-Flare 
sequence. Adapted from [38] and [40]. 
22 
 
2.2.2 Echo Planar Spectroscopic Imaging 
EPSI (proton echo planar spectroscopic imaging or PEPSI in 1H MRSI, Figure 
2.3) was initially proposed by Mansfield [43], and further developed by Posse and co-
workers [44-46]. The echo-planar imaging (EPI) method [43] was adapted by Mansfield 
in CSI to facilitate echo planar shift mapping (EPSM), which was faster than previously 
employed techniques like the 3D/4D Fourier transform [47] and the point-by-point 
topical magnetic resonance method [48]. The EPSI technique was later extended to 3D 
for spectroscopic imaging in the human brain at very short echo times (13 ms) [44, 46]. 
This resulted in acquisition times as low as 64 s, while maintaining an SNR that was 
comparable to that obtained using conventional MRSI techniques [44].  
 
Figure 2.3 A PEPSI pulse sequence with a spin echo excitation section, and an echo-
planar spectral readout. Additional outer volume suppression (OVS) and water 
suppression modules can be added before the 90o pulse. Adapted from [49]. 
 
The EPSI technique accelerates the filling of k-space (up to 3 spatial frequencies 
kx, ky, kz, and time) by acquiring 2 (any one spatial frequency and time ) of the possible 4 
dimensions with each readout [50]. A frequency encoding gradient is rapidly switched 
during readout to acquire both spectroscopic and spatial data from any one k-space 
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dimension, which can subsequently be separated and re-gridded [50]. The acquired 
echoes can be separated into odd and even echoes, and each even (or odd) echo can be 
time-reversed and re-gridded to recover the free induction decays (FIDs) from the 
dimension that the echo planar readout was applied to. Information from the remaining 
two spatial dimensions can then be acquired using conventional phase encoding. Using 
EPSI acquisition in 3D, the time required to collect a 16x16x16 spectroscopic grid is only 
16x16 s (assuming one second per signal acquisition and one average), reducing the scan 
time from 1 hr 16 min to approximately 4 min 16 s. 
However, EPSI has its share of technical limitations. The use of rapidly 
oscillating read out gradients places high hardware demands on the gradient system, 
while the spectral bandwidth is limited by the gradient strength and slew rate [51]. 
Furthermore, only half the spectral bandwidth is used in conventional EPSI as the even 
and odd readout echoes are utilized separately during reconstruction. Limited spectral 
bandwidth is particularly a problem at higher magnetic field strengths (> 3 T) as chemical 
field dispersion effects increase leading to spectral aliasing [51]. Metabolic images tend 
to exhibit ghosting artifacts due to the off resonance effects, also commonly seen in echo 
planar imaging (EPI). This can be compensated for by using a cyclic unwrapping method, 
wherein the aliased portion of the spectrum is cyclically shifted and the region downfield 
is filled with zeros to obtain a modified spectral distribution [51].  
There is a drop in the SNR during data acquisition due to the readout gradient and 
the associated short dwell times (resulting in increased bandwidth and hence noise) as 
compared to conventional MRSI [50]. Due to the stated limitations, increased averaging 
may be required to improve the SNR, which may neutralize the speed gain.  
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Nevertheless, EPSI may be useful in specific applications where loss of SNR is 
acceptable in favor of faster imaging, for e.g. in imaging hyperpolarized probes where 
one battles dynamic signal loss due to T1 [52]. Over the last couple of decades, EPSI has 
been employed in numerous preclinical and clinical studies, also involving non proton 
nuclei such as 13C and 31P [52, 53]. 
 
2.2.3 Non-Cartesian MRSI 
K-space is traversed in a rectilinear manner in conventional MRSI by the choice 
of phase encoding gradients, leading to long acquisition times. Non-Cartesian trajectories 
like the spiral, radial, and less common ones like the rosette, traverse k-space more 
efficiently enabling faster scans. Therefore, non-Cartesian k-space sampling has gained 
increased attention over the years in accelerating MRSI. Spiral MRSI, originally 
developed by Adalsteinsson et al [54] traverses the (kx, ky) space in a spiral trajectory by 
applying gradient waveforms along the x and y axes. The (kx, ky, kω) space is traversed 
by these gradients with the evolution of time. Rewinding gradient lobes are added 
immediately after the spiral gradients to facilitate return to the k-space origin, as depicted 
in Figure 2.4.  
Multiple spiral shots can be employed to map out the entire k-t space and collect 
all data points. The collected data are then interpolated onto a Cartesian k-space grid by 
employing a regridding algorithm for the use of conventional Fourier reconstruction 
techniques [54]. The SNR of the spectra reported by Adalsteinsson et al was found to be 
comparable to that from conventional MRSI techniques using long echo times and 
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inversion recovery pulses for lipid suppression, demonstrating the value of spiral 
trajectories for rapid volumetric spectroscopic imaging. 
 
Figure 2.4 The spiral trajectory in k-space. (a) Trajectory with a rewinding path back to 
the origin, (b) the path traced by the trajectory in (kx, ky, kf) space during the readout 
time, (c) phase encoding used to cover the kz dimension (spherical or ellipsoidal 
coverage), (d) the gradient waveforms over one period, and (e) a pulse sequence diagram 
employing spiral gradients on Gx and Gy to simultaneously encode the x, y, and f 
dimensions. Reproduced from reference [54].  
 
Spiral MRSI has similar constraints and limitations as PEPSI as discussed in the 
previous section, since it applies a readout gradient during data acquisition similar to that 
used in PEPSI. The spiral trajectory tends to be less demanding on the gradient system as 
compared to the EPI waveform. Artifacts can be minimized by carefully calibrating the 
gradient system [37]. The need for sophisticated reconstruction software and lack of 
widespread availability has resulted in limited application of spiral MRSI in the clinic as 
compared to EPSI. Nevertheless, MRSI sequences employing spiral k-space trajectories 
have found numerous applications over the years and continue to be researched and 
developed further. 
Apart from spiral MRSI, there is also potential for developing different novel 
trajectories for the undersampling of k-space [55-58]. Concentrically circular [58], rosette 
26 
 
[56], and various other arbitrary k-space sampling trajectories have been investigated [55, 
57] that can be adopted for MRSI. 
 
2.3   Fast MRSI with Undersampling 
The second major approach undertaken to speed-up MRSI data involves acquiring 
fewer points in k-space and subsequently recreating the complete spatial-spectral 
information either by zero-filling or by employing more advanced non-linear iterative 
reconstruction algorithms. This approach includes techniques like parallel imaging, 
compressed sensing, wavelet encoding, and elliptical sampling. These techniques are able 
to implement sparser sampling as the rectangular extent of the k-space and the properties 
of the Fourier transform allow accurate reconstructions even when certain regions of the 
k-space are not acquired [59]. The reconstructed data from these techniques can be 
viewed as an approximation to the “true” data acquired from transforming the full k-
space. However, the fidelity of such approaches is validated by extensive statistical 
analyses of equivalence up to acceleration factors permitted by the inherent SNR of the 
data under consideration.  
 
2.3.1 Circular & Elliptical Sampling 
The circular sampling technique only measures and samples a circular region in k-
space; the remaining points that have not been collected are zero-filled to produce a 
Cartesian grid for reconstruction using the fast Fourier transform (FFT) [3, 59]. Such a 
technique not only reduces the scan time, but also improves the profile of the point spread 
function (PSF). While circular sampling schemes slightly broaden the main lobe of the 
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PSF, a considerable reduction in the number of side lobes can be achieved by density 
weighting, thus, improving the PSF profile and reducing voxel bleeding [60]. However, 
this technique has its share of limitations. The spatial resolution essentially deteriorates 
and circular sampling creates a highly isotropic PSF, wherein the side lobes of the PSF 
are mainly propagated along the principle axis [3, 60]. Elliptical sampling provides better 
k-space coverage compared to circular sampling, particularly in cases where the spatial 
frequency extent is anisotropic. Spectral definition is accurately maintained, although 
there is a drop in the spatial resolution, similar to circular sampling.   
 
2.3.2 Fast MRSI with Parallel Imaging 
Parallel imaging utilizes multiple receiver coil arrays to permit k-space 
undersampling for accelerating data acquisition [61-63]. Reconstruction of raw 
undersampled k-space data into meaningful images in parallel imaging requires accurate 
knowledge of the coil sensitivities, and can be performed in either the image domain, as 
in sensitivity encoding (SENSE), or in k-space, as in simultaneous acquisition of spatial 
harmonics (SMASH) and generalized autocalibrating partially parallel acquisitions 
(GRAPPA) [63]. In parallel imaging, a typical tradeoff between data acceleration rate and 
the robustness of data reconstruction is an inherent loss in SNR dependent on the 
reduction factor R. An additional potential penalty is the geometry, or g-factor, which 
characterizes the ability of the measured coil sensitivity profiles to reconstruct the 
undersampled k-space raw data. Extensive details on the concepts and principles of 
parallel imaging can be found in the cited literature, and all these parallel imaging 
techniques can be used to speed up MRSI as well. 
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The application of SENSE to spectroscopic imaging is similar to anatomical 
imaging.  In 2D SENSE MRSI, each k-space direction can be undersampled by Rx or Ry, 
resulting in a final undersampling factor of Rx x Ry [62]. This results in an effective n/Rx 
x n/Ry matrix from an originally n x n matrix, resulting in a reduced FOV. Because the 
effective FOV in SENSE MRSI is smaller than the true FOV, the reconstructed image is 
aliased (Figure 2.5) [62]. As in anatomical imaging, the unfolding process requires the 
collection of an accurate sensitivity map from each coil to determine the different weights 
in the superposed signal. Each voxel in the final image is a summation of signals from 
each coil multiplied by the sensitivity of that coil [62, 63]. In the spectral dimension, an 
aliased image at each sampling frequency needs to be unfolded. Using the notation 
followed in reference [61], if S denotes the sensitivity matrix, then the unfolding equation 
described by Pruessmann et al is given by: 
                                                         = 	
		                                                   2.1
 
Where, U is the unfolding matrix, ψ is the receiver noise matrix, and H is the 
transposed complex conjugate. The different weights derived from inaccurate coil 
sensitivity profiles would result in spurious signal artifacts [63].  
In SENSE spectroscopic imaging, the loss in SNR is directly related to the 
reduction factor: the SNR drops by a factor of two when R = 4. The SNR is also affected 
by 1/g, where g is the local geometry factor and is a function of the reduction factor as 
well as coil configuration. Optimal placement of the coils, which in turn is effected by 
trade-offs between single channel noise levels, coil coupling, and geometric and absolute 
sensitivity relations, can help ensure that g is almost close to 1. The SENSE technique is 
not applicable to a single channel coil, and the SNR usually drops for a lower number of 
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coil elements. SENSE encoding can be extended to the third dimension in 3D MRSI to 
obtain further decrease in the scan time. SENSE can also be combined with other high 
speed MRSI techniques like multi-echo MRSI to facilitate very fast imaging times. 
 
 
Figure 2.5 The basic principle behind SENSE MRSI. As an example, the object depicted 
contains two different metabolites as indicated by the color scheme (white and gray 
regions) in (a). A SENSE acquisition of a 16x16 grid shown in (b) results in a 4X 
decrease in the scan time as compared to a conventional 32x32 MRSI grid as only every 
fourth point in k-space is sampled. The resulting aliasing artifacts from Fourier 
reconstruction can be seen in (c). The SENSE reconstruction unfolds the data from voxel 
A, which is a weighted sum of the signal contributions from the four voxels highlighted 
in figure (b) into its components to obtain true signal C at that location. (e) 
Representative in vivo scout (A) and metabolite maps of NAA (B,C), Cr (D, E), and Cho 
(F, G) from conventional (left column, 26 min) and SENSE (right column 6.5 min) MRSI 
for a 32x32 spatial grid. The black voxel depicted in (e) was chosen for SNR 
comparisons between conventional and SENSE spectroscopic imaging. Adapted from 
reference [62]. 
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GRAPPA requires the acquisition of the auto-calibration signal (ACS), which is 
essentially an additional calibration line that is collected along with the reduced data from 
each coil [64]. The data from multiple lines from all coils can be fit to the ACS line from 
a single coil, to generate the reconstruction weights that are used to estimate the missing 
lines. GRAPPA (Figure 2.6) has been tested in 2D and 3D in both 1H and 31P MRSI by 
various groups [65, 66]. 
 
Figure 2.6 Fast MRSI acquisition using GRAPPA. (a) A schematic of the basic 
GRAPPA algorithm. In this example, a single ACS line in coil #4 is fitted using four 
acquired lines. In the GRAPPA technique, a single acquired line along with the missing 
lines present next to that line constitutes a block. A block has been depicted here for an 
acceleration factor of two. (b) An illustration of the application of GRAPPA to 
spectroscopic imaging in a glioma patient. Figure depicting spectra from the tumor region 
of the chosen PRESS volume of interest for (A) a 12x12x8 fully-sampled elliptical 
acquisition, and (B) a 16x16x8 elliptical GRAPPA acquisition. Reproduced from 
references [64] and [67]. 
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2.3.3 Wavelet Encoded MRSI 
The wavelet encoding technique employs prototype wavelet functions (the 
discrete wavelet transform, DWT) to identify defined regions in localized space using 
translations and dilations [68, 69]. The slice selective RF pulse profile is matched to a 
group of dilated and translated wavelets in MRSI. The spin echo sequence in 2D MRSI 
wavelet encoding has single and dual band slice selective excitation and refocusing 
pulses that have profiles similar to the Haar wavelets [68]. The dilations correspond to 
increases in the localization gradients, and translations correspond to the frequency shift 
of the RF pulses, which are represented using the Haar wavelets. The desired resolution 
can be achieved by employing a proportional number of dilations and translations. 
Successive MR signals are acquired from different locations housing regions of variable 
size, without the TR waiting time requirement between successive acquisitions, thus, 
reducing the total scan time [68]. The correct spatial distribution of the MR signal is 
subsequently obtained using an inverse wavelet transform. 
Wavelet encoding permits the imaging of only a selected portion of the FOV in a 
noncontiguous manner. Different subspaces can be excited with no TR waiting time, 
accelerating data collection. As the excitation profiles of the RF pulses are modulated to 
resemble wavelet shapes, there is reduced pixel bleed in the spatial dimensions, which 
can be observed in the corresponding metabolite maps. The SNR in wavelet encoding is 
lower than that in Fourier encoding by almost a factor of two as this technique is limited 
by the length of the wavelet support [68]. In 2D wavelet MRSI, the SNR drops by a 
factor of ( ((N2 + 2)/6)2 ) * (4/N2) for an image of size N x N [68]. More averaging and/or 
less spatially localized wavelets can be employed to achieve a SNR comparable to that 
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found in conventional Fourier encoding. The wavelet encoding technique has also been 
extended to three spatial dimensions in MRSI by Young et al [69].  
 
2.3.4 Compressed Sensing MRSI 
CS is a novel approach that exploits the inherent sparsity of medical images in an 
appropriate transform domain to effectively undersample k-space. This in turn reduces 
the number of samples that are required for reconstruction in MRI and MRSI [70-72]. 
The CS theory successfully predicts that signals can be accurately recovered even when 
sampling well below the established Nyquist rate, if the signals under consideration are 
sparse in some transform domain (not just in the time or frequency domains) [73]. Data 
tend to be sparse in multiple dimensions of space and frequency in the wavelet transform 
domain, thus, making this technique particularly suitable for MRSI. Wavelets have been 
employed to achieve a sparse representation of MRSI data in both the spatial and spectral 
domains, facilitating the application of CS acquisitions in MRSI. 
The CS based reconstruction of undersampled data has to fulfill three main 
requirements, namely, data sparsity, the implementation of pseudo-random 
undersampling, and a non-linear reconstruction algorithm for accurate recovery of the 
signals under consideration. 
 
2.3.4.1 Transform Sparsity 
A ‘sparse’ vector contains all information in a few non-zero coefficients, with all 
other coefficients being zero. ‘Strong’ sparsity is encountered when very few coefficients 
contain all the information in the signal. Most practical applications tend to exhibit 
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‘weak’ sparsity as a transition band exists been the few high-valued coefficients and the 
numerous non-zero coefficients. Most of the signal energy is restricted to these few non-
zero coefficients, while the remaining measurements are essentially zero or close to zero 
[74]. A sparsifying transform operator can be applied to map the image vector under 
consideration to a sparse vector. For e.g. the Fourier transform of a direct current signal is 
a delta function in the frequency domain, which contains all the signal information. Thus, 
a sparse representation of a signal can be obtained by applying the appropriate transform 
operator. Similarly, most MR images tend to be sparse in some transform domain. For 
e.g. angiograms tend to be sparse in the finite differences domain as most of the 
important information is contained in the boundaries [70, 74]. Many sparsifying 
transforms have been developed over the years to facilitate sparse representations of 
different kinds of images [75]. Two particular transforms of interest are the wavelet 
transform and the discrete cosine transform (DCT), which provide a sparse representation 
of several real life images [76]. These transforms have been extensively employed in the 
field of image compression. A multi-scale representation of the image can be obtained 
using the wavelet transform. Fine-scale wavelet coefficients correspond to the high 
resolution image components while coarse-scale wavelet coefficients represent the low 
resolution components [70]. It is important to determine the minimum number of sparse 
coefficients that are required to obtain an accurate reconstruction of the MRSI data [74].  
 
2.3.4.2 Pseudo-random Undersampling of MRSI Data 
The second essential criterion in CS requires the random undersampling of the 
MRSI k-space in order to produce incoherent artifacts that resemble noise [70, 74]. 
34 
 
Uniform k-space undersampling violates the Nyquist criterion producing coherent 
artifacts such as aliasing. While the random selection of k-space samples also violates the 
Nyquist limit, the resulting artifacts are sufficiently incoherent that they can be removed 
by denoising techniques. In the case of MRI/MRSI, the k-space is pseudo-randomly 
undersampled i.e. a certain fraction of the samples are placed at the center of k-space, 
while the remaining samples are randomly distributed in the peripheral k-space region. 
This is necessary as all the information and SNR is confined to the low frequency 
components, which are located at the k-space center. A truly random undersampling of 
the k-space also necessitates rapid gradient switching, which is constrained by the 
hardware and artifacts like eddy currents [71]. The number of required samples depends 
on the level of data sparsity and is usually five to eight times the number of sparse 
coefficients in the transformed data [71, 73]. Thus, identifying the number of sparse 
coefficients is critical to determining the acceleration limit of the CS reconstruction 
algorithm. Finding the ‘optimal’ sampling mask in MRSI continues to be an area of 
research and various approaches to identify the ‘best’ mask at a particular acceleration 
factor will be discussed in detail in Chapter 5 of this thesis. 
 
2.3.4.3 Non-linear Iterative Reconstruction 
The reconstruction of the acquired CS-MRSI data can be formulated as a 
constrained optimization problem, as illustrated in equation 2.2 below [70, 74]: 
                                                                    ‖‖	                                                    2.2
 
                                                    ℎ ℎ    ‖ − ‖ <                                                  
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Where, m is the desired MRSI data to be reconstructed, y is the acquired k-space 
data from the scanner, Fu is the undersampled Fourier operator, ψ is the transform 
operator that provides a sparse representation of the data, and the parameter ε controls the 
tolerance error of the reconstruction. || ||1 and || ||2 are essentially operators representing 
the l1 norm and l2 norm, respectively. Minimizing ‖‖	 enforces sparsity, while the 
data consistency constraint is enforced via ‖ − ‖ <   . A total variation (TV) 
penalty is often included in the objective function in addition to a specific sparsifying 
transform operator. In such cases, the objective function ensures that the MRSI data has a 
sparse representation from both the specific transform as well as from finite differences. 
Equation 2.2 can then be reformulated to include the TV operator as follows [70]: 
                                                      ‖‖	 +  "#$
                                           2.3
 
                                           ℎ ℎ    ‖ − ‖ <                                                 
Wherein the operator α trades the sparsity from the finite differences and the ψ 
operator. Employing the Lagrange method, Equation 2.3 can recast as an unconstrained 
optimization problem that involves minimizing the following equation [70, 74]: 
                                       &'  ‖ − ‖ + (	‖‖	 + (#$
                           2.4
 
Where, (	 and ( are regularization parameters that need to balance the data 
consistency and sparsity terms. An iterative non-linear reconstruction algorithm such as 
the steepest descent method or the non-linear conjugate gradient technique can be 
employed to solve for the desired MRSI data m in Equation.  For e.g. in the conjugate 
gradient algorithm, Equation is differentiated to determine the direction of the gradient 
each time. A line-search parameter is incorporated to evaluate the step-length to be 
advanced in the gradient direction. Convergence in the iterations is obtained when a) 
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there is negligible difference in the tolerance parameter values between successive 
iterations, and b) the tolerance parameter value is lower than the selected ε value. The 
total number of iterations required to obtain convergence in the cost function is 
dependent on problem at hand and the type of data being evaluated. 
 
Figure 2.7 (a) An illustration of pseudo-random undersampling in CS. (b) various 
domains and operators in CS. 
 
The first application of CS to MR imaging was by Lustig et al [70]. The 
application of CS to 1H MRSI was investigated by Geethanath et al for various 
acceleration factors, retrospectively [71]. Sampling masks were generated for various 
acceleration factors, namely, two, three, four, five, and ten using variable density random 
undersampling. A two dimensional probability density function was used to select the 
random samples, ensuring a denser sampling at the center of k-space and sparser 
sampling of points towards the periphery [71]. The reconstructions at various acceleration 
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factors preserved the fidelity of the metabolite spectrum when compared with the fully 
sampled conventional MRSI datasets. The algorithm broke down at an acceleration factor 
of ten, wherein the metabolite peaks began to show increased signal intensities when 
compared to the conventional MRSI datasets. The reconstruction, thus, faithfully 
preserved the prognostic and diagnostic value of the metabolite maps up to an 
acceleration factor of five; this retrospective study was an important first step that 
demonstrated the feasibility of the approach (Figure 2.7) [71].  
CS has been employed to accelerate multidimensional spectroscopic imaging in 
recent clinical studies [77-79]. A 4D echo planar imaging sequence based on J-resolved 
spectroscopy was implemented using CS to achieve a high acceleration in vivo, 
demonstrating the utility of multidimensional MRSI [77-79]. The CS technique has also 
been applied to 13C 3D MRSI, in the design and testing of a CS based new EPSI sequence 
[80, 81]. Hyperpolarized 13C data are well suited for CS applications due to the 
fundamentally sparse spectrum and high SNR resulting from hyperpolarization [80, 81]. 
The T1 decay of the hyperpolarized signal restricts the amount of time available for signal 
acquisition in the time-window when SNR is high, thus, necessitating the use of 
accelerated imaging techniques for optimal spatial coverage and speed. The sequence 
proposed by Hu et al achieves an acceleration factor of up to 7.53, and minimal artifacts 
in the reconstruction for 3D MRSI [81]. A time-resolved 3D MRSI technique has been 
developed by Larson et al [82] for monitoring the dynamics of pyruvate conversion to 
alanine and lactate in a mouse model. This method effectively utilizes the magnetization 
through the use of multiband excitation pulses in combination with CS for increased 
acceleration [82].  
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Figure 2.8 The retrospective application of CS-MRSI demonstrated in a brain tumor 
patient. Representative metabolite maps of NAA, creatine (Cr), choline (Cho), and 
choline to NAA index (CNI) for various acceleration factors. Reproduced from reference 
[71]. 
 
The CS technique has also been applied to 31P MRSI of the human brain by Askin 
et al [83]. The long scan times associated with 31P MRSI restrict its widespread use in the 
clinic. Furthermore, 31P MRSI requires larger voxels and increased signal averaging to 
obtain adequate SNR as the signal from 31P is approximately 15 times less MR sensitive 
than that from protons. In this study, a higher SNR was observed in the CS reconstructed 
data, while the peak height ratios of the original and CS datasets were comparable [83]. 
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Recent promising preclinical applications of CS MRSI in vivo include 19F 3D 
spectroscopy in mice [84] wherein the non-existent background signal in 19F MRSI 
makes it particularly suited to satisfy the sparsity constraint that is integral to CS. 
Exogenously administered 19F MRSI has several markers with unique spectral signals 
that can be well detected in the presence of a negligible background signal. Kampf et al 
demonstrated the retrospective application of CS based 19F MRSI both in vitro and in 
vivo, with the CS reconstructions preserving the fidelity of the data up to an acceleration 
factor of 8 [84]. The first application of high resolution 23Na spectroscopic imaging in 
mouse hearts was recently demonstrated by Maguire et al [85]. The 23Na MRSI data from 
in vivo mouse hearts were prospectively undersampled by 3X and reconstructed using the 
CS algorithm previously described in [71], to yield undersampled reconstructions that 
preserved the fidelity of the data. 
 
2.3.5 Hybrid Fast MRSI & Other Contributions 
The two major categories of MRSI acceleration techniques are not exclusive and 
various novel combinations can be implemented to gain more speed, as has been the case 
in MRI. Various methods have been broadly classified into the discussed two main 
categories according to the dominant effect and there are no efforts to suggest exclusivity 
of these two categories when describing any technique. Various studies have focused on 
combining acceleration techniques to further reduce scan times and overcome some of 
the limitations of individual high-speed techniques in MRSI [86-91]. All these hybrid 
techniques try to achieve the best trade-off between gain in speed and optimal SNR, 
resolution, and resulting artifacts. 
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2.4   Implications of Accelerated MRSI & Future Directions 
The future holds promise for the development of various hybrid techniques, 
particularly those involving CS, parallel imaging, and novel k-space trajectories, to 
achieve further reduction in scan times and better image quality in terms of the SNR, 
spatial and temporal resolution, and artifact reduction. CS based pulse sequence design 
has several potentially beneficial implications in the clinical scenario. Larger matrices 
offer more sparsity to exploit and the increased room for undersampling could lead to 
even higher acceleration factors. This technique could also be used to cover larger FOVs 
in the clinical setting. Gradient amplitude constraints would not impose a limitation on 
the design as the FOVs in clinical applications tend to be at least an order of magnitude 
higher than those typically used in preclinical studies. CS reconstructions can be used to 
further accelerate scan times when datasets of higher order dimensions are collected. The 
inherent sparsity along an increased number of dimensions can be fully exploited by only 
collecting specific phase encode values along each additional spatial dimension. 
Furthermore, a key point to be noted is that the benefits of under-sampling along the 
temporal dimension are not as significant as those along the phase encode dimensions 
due to the nature of MR signal acquisition. One exception is the EPSI approach, which 
(even under fully sampled conditions) does not sample the time dimension continuously 
and hence lends itself to temporal under-sampling quite well [50]. However, more 
sophisticated reconstruction routines could be developed even for conventional readouts 
to exploit sparsity along the spectral dimension, with a goal of improving SNR or further 
reducing the scan time. 
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All discussed high-speed MRSI techniques have been extensively employed in 
studies of the brain and to a large extent in the prostate. However, there is limited 
research in other organs like the breast, abdomen, etc. The application of MRSI to many 
other organ systems is often limited by low SNR, contamination from peripheral lipid 
signals (in turn restricting short TE acquisitions), higher field inhomogeneity, and motion 
artifacts. With increasing acceleration, a drop in SNR is observed when employing fast 
techniques, except in CS where denoising leads to improved SNR at higher acceleration 
factors. Other aspects to be considered include eddy current artifacts, the achievable 
spatial resolution, and the need for fast gradient systems that are often not implementable 
due to hardware limitations. Non-proton MRSI is also limited by very low MR signal 
sensitivity, making its clinical translation difficult. 
Several processing steps are usually required for the complete analysis of MRSI 
data, and the processing methods vary for different data types as well [23]. This 
technique is less appealing to the radiologist due to a lack of standardization in MRSI 
acquisition protocols, and the non-availability of common processing and analysis tools 
for a quick and simple representation of metabolite concentration maps. Automation and 
quality control are of critical importance in accelerated MRSI techniques that frequently 
experience poor spectral quality due to SNR losses, lipid contamination, hardware 
limitations, and miscellaneous other artifacts. Ultra-fast CSI acquisition techniques also 
necessitate the use of more sophisticated reconstruction algorithms and complex spatial-
spectral analysis to minimize the reconstruction errors from the sparse acquisitions. 
Implementation of advanced algorithms and routines on the scanner for ‘on the fly’ 
reconstruction and complex spectral analysis is not a trivial task. One must also take into 
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account the additional time required for reconstruction, post processing, and display of 
metabolite maps. Furthermore, it is important to note that high-speed MRSI techniques 
are only acceptable in applications wherein conventional phase-encoded MRSI is itself 
not SNR limited at the desired spatial resolution. The SNR penalty in conventional MRSI 
is often large to begin with, particularly when imaging difficult regions, which tends to 
get further aggravated when employing accelerated CSI techniques. 
Another concern in spectroscopic imaging is the effect of the acceleration 
technique on the PSF and cross-contamination of information between neighboring 
voxels. For e.g. in turbo MRSI, the reduced echo duration caused a broadening of the 
spectral PSF, with phase distortions leading to further PSF degradation [36]. Variable 
density-weighted trajectories tend to suppress the side lobes of the PSF as compared to 
uniformly-weighted/non-weighted acquisition schemes. Spiral sampling trajectories also 
tend to have reduced ringing and a narrower central PSF lobe as compared to the 
elliptical sampling scheme; variable-density spirals can be employed to further reduce the 
side lobes and ringing [92]. In SENSE spectroscopic imaging, the spatial response 
function (SRF) tends to slightly vary between voxels and is affected by the sensitivity 
relations [62]. In wavelet-encoded MRSI, the PSF is a function of the wavelet shape, and 
in turn of the RF pulse profile [69]. In fast techniques like CS, a coherent broadening of 
the PSF is avoided due to the incoherent nature of undersampling, resulting in noise-like 
artifacts [70, 71]. On the other hand, high-speed techniques can help in reducing blurring 
and streaking artifacts, especially while imaging organ systems that are susceptible to 
motion. Fast MRSI will also aid in higher volume coverage, incorporation of specialized 
techniques like spectral editing for mapping metabolites like lactate and gamma-amino-
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butyric acid (GABA) that typically require more averaging to obtain optimal SNR. Other 
techniques like J-resolved spectroscopy and correlation spectroscopy (COSY) could also 
be incorporated into current clinical protocols to obtain high resolution spectroscopy data 
[77, 79, 93].  
Thus, the acceleration offered by high-speed techniques can either be employed to 
decrease the scan time, leading to reduced motion sensitivity and patient discomfort, or 
the time-saving can traded for higher SNR/resolution and/or for imaging a larger volume 
of interest. The reconstruction and quantification of sparsely-sampled spectroscopic data 
on the scanner immediately following data acquisition will also help establishing the need 
for inclusion of fast MRSI techniques into current imaging protocols. 
  
(Note: Chapter 2 is based on the paper – “Fast Data Acquisition Techniques in Magnetic 
Resonance Spectroscopic Imaging”, R. Vidya Shankar, J. C. Chang, H. H. Hu, and V. D. 
Kodibagkar, Submitted to NMR in Biomedicine, under review.) 
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CHAPTER 3 
PRE-CLINICAL APPLICATIONS OF CS-MRSI 
 
MRSI has several applications in the preclinical setting for a non-invasive 
mapping of biochemistry in vivo. The objective of this study was to accelerate spectrally-
edited MRSI on a preclinical MRI scanner to achieve rapid spectroscopic imaging of 
lactate levels in solid tumors and evaluate subsequent changes in response to therapy. 
 
3.1   Lactate-selective CS MRSI 
3.1.1 Why Image Lactate? 
Lactate plays a critical role in the development and metastasis of cancer, and its 
accumulation is readily seen in solid tumors [30, 94]. Under normoxic conditions, 
glucose metabolism is a highly energy efficient process, producing 38 adenosine 
triphosphate (ATP) molecules on the complete oxidation of one glucose molecule, along 
with water and CO2 [95]. In differentiating cells, glucose is converted to lactate (via 
pyruvate, Figures 3.1 and 3.2) when oxygen is limited to produce 2 ATP 
molecules/glucose molecule. However, even in the presence of ample oxygen, cancer 
cells tend to preferentially metabolize glucose by aerobic glycolysis, which is a less 
efficient pathway for ATP production, generating only 4 ATP molecules/glucose 
molecule as compared to oxidative phosphorylation [30, 94-96]. This phenomenon is 
known as the Warburg effect [96], wherein glucose is preferentially catabolized to lactate 
in the presence of adequate oxygen. Thus, the build-up of lactate in solid tumors is 
suggestive of altered metabolism and possibly indicates the presence of hypoxia. 
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Lactic acid has also been found to stimulate angiogenesis, promote inflammation, 
and contribute to the immune escape [30, 94]. The elevated lactate levels seen in biopsy 
samples have been suggestive of an increased risk of tumor metastasis, recurrence, and 
radio resistance leading to poor therapeutic outcomes in cancers of the head and neck, 
breast, and cervix, while cancer response to chemotherapy has indicated a decrease in the 
steady-state tumor lactate levels [97-102]. A dedicated technique like magnetic resonance 
spectroscopic imaging (MRSI) can be employed for mapping the spatial distribution of 
lactate in solid tumors in vivo. This could potentially lead to improved cancer targeting 
and therapy, and the possibility of employing non-invasive lactate imaging as a 
prognostic marker in the clinic to monitor the dynamic changes in lactate concentration 
both pre- and post-therapy [103-105]. 
 
 
Figure 3.1 An illustration of cellular energy processes, namely, oxidative 
phosphorylation, anaerobic glycolysis, and aerobic glycolysis (also called the Warburg 
effect). Reproduced from [96]. 
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Figure 3.2 The role played by lactate in various cancer pathways and processes. 
Reproduced from [94]. 
 
3.1.2 Lactate Detection in Proton MRSI 
As previously discussed in Chapter 1 section 1.3.4, lactate is essentially a J-
coupled metabolite, with the methine (-CH) and methyl groups (-CH3) forming an A3X 
spin system [29]. Even at low magnetic fields, the scalar-coupled spin system of lactate is 
considered to be weakly coupled [24]. The -CH3 moiety is responsible for the doublet 
located at 1.31 ppm in the NMR spectrum, while the –CH moiety is responsible for the 
quartet at 4.1 ppm (Figure 3.3). The doublet is more commonly acquired but accurate 
detection and quantification are often complicated by the presence of macromolecules 
and huge overlapping resonances from lipid in the 0.8 – 1.3 ppm range. It is often 
difficult to detect the quartet at 4.1 ppm in vivo due to its proximity to water. To 
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overcome the above limitations, several spectral editing techniques have been developed 
for accurate acquisition of the lactate resonance [106-108]. Longer echo times (TE) are 
usually employed when acquiring the lactate peak to minimize contamination from the 
lipid resonances.   
 
Figure 3.3 An illustration of the lactate molecule and its corresponding NMR spectrum. 
The CH3 group produces the doublet at 1.31 ppm, while the CH moiety is responsible for 
the quartet located at 4.1 ppm. 
  
3.1.3 The Sel-MQC Sequence 
Spectral editing techniques seek to separate the overlapping resonances and 
quantify the harder to detect metabolites like lactate, citrate, GABA (γ-Aminobutyric 
acid), and 2-hydroxyglutarate (2HG) to name a few. Such low concentration metabolites 
can be selectively recorded with specific acquisition schemes that retain only the 
metabolite peaks of interest, while eliminating any interfering resonances particularly 
those from water and fat [109]. Pulse sequence optimization and a strict assessment of the 
specificity achieved by the editing technique will ensure a more reliable detection of 
these smaller metabolites [109]. 
The selective multiple-quantum coherence transfer (Sel-MQC) sequence 
developed by He et al [106] is one such spectral editing sequence that achieves selective 
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excitation of the lactate doublet, while effectively suppressing the peaks from lipid and 
water. A 2D MRSI implementation of the Sel-MQC sequence is depicted in Figure 3.4 
(adapted from [106]), and involves the three distinct stages elucidated below for lactate 
excitation, selection, and detection. 
(a) Preparation 
The first part of the pulse sequence involves converting the lactate resonance into 
the multiple quantum coherence (MQC) state. A frequency-selective 90o RF pulse 
is applied to excite fat and the CH3 moiety corresponding to the lactate doublet. 
Scalar coupling (J), chemical shifts (ω0), and B0 field inhomogeneity effects 
contribute to the evolution of these single quantum coherences (SQCs). Following 
time τ = 1/2J, where J = 6.93 Hz for lactate, a second 900 pulse is applied at the -
CH peak frequency to convert the lactate magnetization into the MQC (zero and 
double quantum coherences, ZQ and DQ) mode, while all other resonances 
remain in the SQC mode.  
(b) Gradient Selection & Labeling 
A set of coherence selection gradients, namely g1, g2, and g3, are applied in a 
specific ratio to select either the ZQ  DQ (0:-1:2) or DQ  ZQ (1:0:2) pathway 
of lactate. These coherence selection gradients act as a multiple quantum filter 
allowing only the MQCs from lactate to pass through, while at the same time 
dephasing all resonances in the SQ mode. The CH3-selective 180
o pulse applied in 
the middle of the gradient labeling period helps to refocus the B0 inhomogeneity 
and chemical shift, and eliminate J-modulation effects.   
(c) Detecting the lactate doublet 
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The final stage of the pulse sequence involves acquiring the lactate doublet. A 
CH-selective 90o ‘read’ pulse applied at the beginning of the detection period 
converts the MQCs of lactate back into the SQ mode. This is necessary as the 
final signal can only be detected and acquired when in the SQ mode. The gradient 
g3 applied during the time interval τ’ = τ – t1 (for the chosen ZQ → DQ pathway, 
figure not to scale) refocuses the pathway selected during the prior gradient 
labeling period.        
 
Figure 3.4 A 2D MRSI pulse sequence with lactate-specific editing based on the Sel-
MQC technique. Adapted from [106]. 
 
Selection of either the ZQ  DQ or DQ  ZQ pathway allows a 50% recovery 
of the lactate signal intensity. Both pathways need to be refocused simultaneously to 
obtain complete recovery of the lactate signal. All other resonances experience a set of 
unbalanced gradients and are completely dephased.  
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3.1.4 Key Aspects to Fast Lactate Imaging 
The aim of this study was to achieve rapid imaging of the lactate resonance by 
implementing a 2D MRSI version of the Sel-MQC sequence, with pseudo-random 
undersampling of the phase encodes Gx and Gy (shown in Figure 3.4) to facilitate CS 
acquisition and reconstruction. A schematic of the proposed fast lactate imaging method 
is depicted in Figure 3.5.  
 
Figure 3.5 An illustration of the two key aspects in fast lactate imaging, namely lactate-
selective spectral editing (SelMQC [106], SS-SelMQC [107]) and CS acquisition and 
reconstruction [70, 110].   
 
The objective of this study was to incorporate spectral editing components for the 
selective excitation of the lactate resonance along with prospective undersampling of the 
k-space to facilitate rapid CS accelerated MRSI of lactate in vivo. The nuisance signals 
are filtered out by spectral editing leading to a reliable detection of the lactate peak. 
Combined with CS acquisitions, the developed sequence, referred to henceforth as the 
lactate-CS-MRSI sequence, with enable the high-speed detection of lactate with finer 
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precision. The implementation of the proton lac-CS-MRSI sequence and its applications 
both in vitro and in vivo will be elucidated in the following sections. 
 
3.1.5 Materials & Methods 
MRSI Pulse Sequence for Rapid Lactate Mapping 
The lactate-CS-MRSI pulse sequence, depicted in Figure 3.4, was developed in 
the Bruker ParaVision 5.1 environment. Two key modifications were made to a 
conventional MRSI pulse sequence: (1) Spectral editing components based on the 
SelMQC technique [106] were added to enable selection of the ZQ  DQ pathway of 
lactate. (2) Pseudo-random undersampling patterns that were generated ‘on the fly’ on the 
scanner (based on the acceleration factor input by the user) were employed to 
undersample the phase encodes Gx and Gy depicted in Figure 3.4 to facilitate prospective 
CS acquisitions. 
 
MRSI Data Acquisition 
All experiments were conducted on a Bruker BioSpec® 7 Tesla (7T) preclinical 
magnetic resonance imaging (MRI) scanner. The developed lactate-CS-MRSI sequence 
was initially tested and optimized on phantoms containing deionized water/oil/lactate (5 
mM). MR acquisition parameters were as follows: 16 x 16 x 4096 matrix, 40 x 40 mm2 
FOV, TE/TR = 144/1500 ms, 2 mm slice thickness, number of averages = 1, spectral 
width = 4006.41 Hz, dwell time = 249.6 µs. In vivo studies involved cohorts of nude mice 
subcutaneously implanted with H1975 (non-small cell lung cancer, nsclc) tumors in the 
right thigh. All animal studies were approved by the Institutional Animal Care and Use 
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Committee. A cohort of n = 6 nu/nu tumor mice was employed for testing and optimizing 
the lactate-CS-MRSI sequence in vivo. Tumors were allowed to grow to 1 cm3 prior to 
conducting MRSI experiments. Animals were passively restrained throughout the 
experiment and were anesthetized via isoflurane gas inhalation (1.5 %). In vivo 
experiments were conducted using a surface receive coil combined with a 72 cm volume 
transmit coil. The subcutaneous thigh tumor was carefully placed under the surface coil 
and the animals were positioned on a warm heating pad connected to a circulating water 
bath set to operate at 37 oC, to keep them warm during the experiment. The fully sampled 
reference MRSI acquisition (1X), along with datasets corresponding to various 
acceleration factors, namely 2X-5X and 10X, were acquired for each experiment. MR 
scan parameters: 16 x 16 x 2048 matrix, 27.2 x 27.2 x 3 mm3 FOV, TE/TR = 144/1500 
ms, number of averages = 8, spectral width = 4006.41 Hz, dwell time = 249.6 µs. 
 
CS-MRSI Reconstruction 
A custom non-linear iterative reconstruction based on the conjugate gradient 
algorithm was implemented in Matlab (The Mathworks Inc., MA) to reconstruct all the 
lactate-CS-MRSI datasets. The CS-MRSI reconstruction was formulated as a convex 
optimization problem, which involved minimizing the following cost function [71]: 
                                  Є
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where, y is the measured k-space data, m is the desired MRSI data, Fu, W, and TV 
are the Fourier transform, wavelet transform, and total variation operators, respectively, 
||.||1 and ||.||2 are the /	 and / norm operators, respectively, and, λLI and λTV are the 
corresponding regularization parameters for the L1 norm and TV operator, respectively. 
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The kx - t matrix was encoded along each of the two dimensions using the Daubechies 
wavelet transform at all points in ky. The regularization terms λTV and λLI were 
experimentally determined to be 0.005 and 0.001, respectively. Eight iterations were 
found to be optimal to obtain convergence of the cost function.  
 
Post processing, Error Metric and Statistical Analysis 
All reconstructed lactate CS-MRSI datasets were quantitatively compared with 
the 1X fully sampled reference dataset by evaluating metrics like the SNR, lactate peak 
amplitude, and the total acquisition time. In each case, the error in reconstruction, as 
defined by the root mean square error (RMSE) metric was calculated as: 
                                                     012 =  314 56 − 67
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Where, N is the total number of points in the MRSI dataset, y is the reconstructed 
data from the fully-sampled (1X) k-space, and y’ is the data reconstructed from 
undersampled k-space. The RMSE defined here can be considered to be equivalent to the 
normalized RMSE as the data range was normalized from 0 to 1. The jMRUI [111] 
software package was employed to apply the following minimal post-processing 
operations to all the reconstructed MRSI datasets: (a) apodization to eliminate any 
truncation artifacts, (b) automatic/manual zero and first order phase correction, and (c) 
Generation of lactate maps using AMARES [111]. 
A voxel-wise 2-tailed paired t-test was applied to the lactate maps generated from 
each reconstructed dataset with the fully sampled reference dataset using the GraphPad 
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Prism (San Diego, CA, USA) scientific software. A p-value < 0.05 was considered 
statistically significant and indicative of an incorrect reconstruction. 
 
3.1.6 Results 
Figure 3.6 shows results from the phantom experiments. The lactate-CS-MRSI 
sequence was able to eliminate the water and fat resonances, while enabling selection of 
lactate from the innermost tube of the phantom. Undersampled MRSI datasets 
corresponding to acceleration factors 1X – 10X were prospectively acquired and 
reconstructed using the procedures outlined previously.  
 
Figure 3.6 The water/oil/lactate (5 mM) phantom. An illustration of reconstructed MRSI 
datasets corresponding to different undersampling factors (from left to right): 1, 0.5, 0.33, 
0.25, 0.2, 0.17, 0.14, 0.12, 0.11, and 0.1, respectively.  
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Total acquisition time – 6 min 30 s (1X), 3 min 18 s  (2X), 2 min 7 s (3X), 1 min 
36 s (4X), 1 min 17 s (5X), 1 min 6 s (6X), 54 s (7X), 47 s (8X), 42 s (9X), and 38 s 
(10X). As can be seen from the figure, the CS-MRSI reconstructions of the lactate peak 
maintain good fidelity even up to 10X, with no statistical significance seen between the 
fully sampled 1X reference and undersampled reconstructions (i.e. p > 0.05).  
The developed sequence was subsequently tested in vivo in a cohort of nu/nu mice 
(n = 6) subcutaneously implanted with H1975 (non-small cell lung cancer, nsclc) tumors 
in the right thigh. The results from the in vivo experiments are depicted in Figures 3.7 - 
3.9. In Figure 3.7, all reconstructions 1X – 5X show the same distribution of lactate and 
no statistically significant differences were observed expect between 1X and 4X (p < 
0.05). Figure 3.9 shows additional results from the in vivo cohort (same acquisition 
parameters), with 2X – 5X lactate reconstructions maintaining high accuracy with the 1X 
reference.     
The RMSEs from the phantom experiment are shown in Figure 3.8 (a). The 
RMSE remains below 5% for accelerations up to 6X, with increasing deviations seen 
with increasing acceleration. However, even between 7X – 10X, the RMSE was found to 
be under 8%, with high accuracy in the reconstruction of the lactate peak. Figure 3.8 (b) 
depicts the mean nRMSE ± standard deviation for the in vivo cohort of H1975 mice. As 
seen in the figure, reconstruction errors are between 2% - 6% for reconstructions 2X – 
5X. The low standard deviation values, particularly at 3X and 4X indicate consistent 
reconstruction errors in the entire cohort of n = 6 animals. 
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Figure 3.7 Reconstructed MRSI datasets showing the distribution of lactate in a H1975 
tumor implanted subcutaneously on a mouse thigh. Total acquisition time – 51 min 12 s 
(1X), 25 min 36s (2X), and 10 min 24 s (5X). The p-value for the 1X vs 2X case is 0.26, 
while that for the 1X vs 5X case is 0.49, indicating no statistically significant differences 
(p>0.05) between the undersampled and fully-sampled reference reconstructions. 
 
 
Figure 3.8 RMSEs from the in vitro and in vivo experiments. (a) The normalized RMSEs 
from the phantom experiment for acceleration factors 2X – 10X. (b) The mean nRMSEs 
± standard deviation for the H1975 cohort.  
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Figure 3.9 Lactate-CS-MRSI datasets from the in vivo cohort. High fidelity can be seen 
between the 1X and 2X – 5X reconstructions of the lactate peak (p > 0.05). 
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3.2   Assessment of Lactate Changes using Combretastatin A4 Phosphate 
3.2.1 CA4P 
The lactate-CS-MRSI sequence was also used to assess the dynamic changes in 
cancer metabolism in response to therapy using the prodrug combretastatin A4 phosphate 
(CA4P) [112-114]. CA4P is essentially a tubulin-binding agent that rapidly disrupts and 
shuts down the tumor vasculature upon administration. The vascular endothelium of the 
tumor is an important target in cancer therapeutics as the continued growth and survival 
of solid tumors is heavily dependent on the vasculature, which sustains malignant growth 
by supplying oxygen and nourishment [114]. Thus, disrupting the vascular functionality 
of cancer cells is a key approach to a quick and catastrophic destruction of the tumor, by 
inducing nutrient deprivation and hypoxia [113, 114]. CA4P belongs to the class of 
compounds isolated from the South African tree Combretum caffrum [113], and is 
responsible for causing fast and prolonged interruption of blood flow leading to extensive 
necrosis in the tumor cells within 24 hours of administration (Figure 3.10).   
Various qualitative and quantitative techniques have been employed to capture the 
rapid changes in solid tumors induced by CA4P treatment [115-123]. Modalities like 
positron emission tomography (PET) measure changes in tumor perfusion and blood 
volume using 15O-labeled water (H2
15O) and carbon monoxide (C15O) [117]. The 
increased glucose uptake by solid tumors as compared to normal tissues can be exploited 
for tumor diagnostics, anti-cancer therapy, and in the detection of metastasis using FDG-
PET. Other imaging modalities include in vivo near infrared spectroscopy (NIR) 
combined with diffusion weighted (DW) MRI to monitor changes in vascular perfusion, 
tumor oxygenation (pO2) and necrosis in response to CA4P treatment [121], NIR 
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combined with laser Doppler flowmetry to assess variations in blood flow and perfusion 
[116], fluorescence and bioluminescence imaging (BLI) to measure light emission 
kinetics [123], and dynamic contrast enhanced (DCE) computed tomography (CT) for a 
quantitative evaluation of the spatial heterogeneity in tumor vascularity as a marker of 
angiogenesis over the entire tumor volume [119]. Various MRI techniques have also been 
implemented to capture tumor dynamics upon CA4P administration, such as DCE MRI to 
study vascular permeability and perfusion [118], dynamic bioluminescence imaging 
(BLI) combined with MRI to examine changes in tumor growth and pO2 [120], and MRS 
[124, 125] to map key metabolite concentrations (for e.g. lactate, choline, and citrate). 
 
Figure 3.10 The mechanism of action of a vascular disrupting agent such as CA4P 
depicted in (a) and the CA4P molecule in (b). Results from DCE MRI both pre- and 24 
hours post CA4P injection illustrated in (c), indicating a significant decrease in tumor 
perfusion. Reproduced from [126] and [118].    
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3.2.2 Methods 
MRSI Experiments 
Additional in vivo experiments were conducted to assess the effects of CA4P in 
altering the lactate metabolism of H1975 tumors. The lactate-CS-MRSI sequence was 
used to assess pre- and post CA4P treatment lactate levels for various acceleration 
factors. A cohort of n = 5 nu/nu tumor mice was treated with the CA4P prodrug (83 
mg/kg body weight) and spectroscopic data was acquired using the lactate-CS-MRSI 
sequence both pre- and post-therapy. The general imaging sequence that was adopted 
while imaging each mouse is as follows: Baseline lactate-CS-MRSI scan (1X and 2X, 
5X) – Inject CA4P – lactate-CS-MRSI scan (5X) – wait 24 hours – lactate-CS-MRSI 
scan (1X and 2X, 5X). A second cohort of n = 5 nu/nu tumor mice was injected with 
dextrose and served as the control cohort. The same general imaging sequence described 
above was also adopted for the control cohort, and the lactate-CS-MRSI sequence was 
employed to acquire dynamic MRSI data both pre- and post-injection of dextrose.  
 
3.2.3 Results 
The results from the CA4P experiments are depicted in Figures 3.11 – 3.13. In 
each of the illustrated figures, the top panel shows the baseline lactate maps (1X, 2X, and 
5X) from day zero i.e. prior to the injection of CA4P, while the bottom panel shows the 
corresponding lactate maps (1X, 2X, and 5X) from the same tumor cross-section 24 
hours post the injection of the prodrug. All MRSI datasets were acquired with the 
following scan parameters: 16 x 16 x 2048 matrix, TE/TR = 144/1500 ms, 3 mm slice, 
Navg = 4, FOV 3 x 3 cm
2, 1X scan time = 25 min 36 s. In four of the five animals of the 
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CA4P cohort, a decrease in total lactate levels was quantitatively measured 24 hours after 
the injection of CA4P, as can be observed from the lactate maps and the total integrated 
intensity of the lactate peak collated in Table 3.1. An increase in lactate was measured in 
one animal from the cohort 24 hours post administration as seen in Figure 3.13 (mouse 5 
in Table 3.1).  
A second cohort of nu/nu mice (n = 5) subcutaneously implanted with H1975 
tumors in the right thigh served as the control cohort and were injected with dextrose. 
Figure 3.14 shows the results from the control cohort acquired with the same scan 
parameters listed earlier. The top panel shows the baseline lactate maps (1X, 2X, and 5X) 
from day zero i.e. pre dextrose injection, while the bottom panel shows the corresponding 
lactate distribution (1X, 2X, and 5X) measured from the same tumor cross-section 24 
hours after the administration of dextrose. As expected, no significant changes were seen 
the total lactate distribution 24 hours post dextrose injection in the control cohort. The 
lactate maps from both the CA4P and control cohorts also indicate that the prospectively 
acquired accelerated reconstructions 2X and 5X maintain high fidelity with the 1X fully 
sampled reference MRSI dataset in each animal, as can be observed in Figures 3.11 – 
3.14. Table 3.1 summarizes the lactate integrated intensities and pre/post ratios for 
accelerations 1X and 5X from both the CA4P and control cohorts. 
The mean nRMSEs ± standard deviations from the CA4P and control cohort both 
pre and post injection in each case are depicted for accelerations 2X and 5X in Figure 
3.15 (a) and (b), respectively. In both cohorts, the reconstruction error remains below 3% 
for the 2X, while the error does not exceed 5% in case of the 5X reconstructions.  
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Figure 3.11 Lactate distribution as mapped by MRSI in a H1975 tumor (CA4P M1, 
Table 3.1) in response to CA4P treatment. Top panel: lactate maps before CA4P 
injection, lower panel: lactate distribution in the same tumor cross-section 24 hours post 
CA4P injection. 1X pre/post = 295/206 a.u. and 5X pre/post = 311/201 a.u., mean 
integrated intensity (scale bar 0 – 4 a.u.). 
 
 
Figure 3.12 Lactate distribution in a second H1975 tumor (CA4P M3, Table 3.1) pre and 
post injection of CA4P. 1X pre/post = 473/446 a.u. and 5X pre/post = 466/427 a.u., mean 
integrated intensity. 
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Figure 3.13 Lactate distribution in a third H1975 tumor (CA4P M5, Table 3.1) pre and 
post injection of CA4P. 1X pre/post = 428/476 a.u. and 5X pre/post = 413/465 a.u., mean 
integrated intensity. 
 
 
Figure 3.14 Lactate distribution as mapped by MRSI in a H1975 tumor in response to 
injection of dextrose. Top panel: lactate maps before dextrose injection. Lower panel: 
lactate maps 24 hours post dextrose injection. 1X pre/post = 278/263 a.u. and 5X pre/post 
=269265 a.u. mean integrated intensity. 
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Table 3.1 Lactate integrated intensities (arbitrary units) and ratios for the CA4P and 
control cohorts (Ratio = Pre/Post). 
 
Cohort 1X 5X 
Pre Post Ratio Pre Post Ratio 
 
 
CA4P 
M1 295 206 0.7 311 201 0.65 
M2 507 461 0.9 529 448 0.85 
M3 473 446 0.94 466 427 0.92 
M4 513 450 0.88 504 462 0.92 
M5 428 476 1.11 413 465 1.13 
 
 
Control 
M1 475 481 1.01 454 469 1.03 
M2 278 263 0.95 293 261 0.89 
M3 239 218 0.91 225 221 0.98 
M4 379 386 1.02 390 394 1.01 
M5 327 339 1.04 311 322 1.04 
 
 
Figure 3.15 The normalized RMSEs corresponding to accelerations 2X and 5X, both pre 
and post injection of the probe, for the (a) CA4P and (b) control cohorts. 
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The low standard deviation values also indicate very less variation in the nRMSE 
across a particular cohort as seen in Figure 3.15 and the trend seen is as expected. 
Additional statistical analysis was performed on the datasets from both the CA4P and 
control cohort, as depicted in Figure 3.16. In the first instance, only four mice from the 
CA4P cohort that showed a decrease in the total lactate integrated intensity post 24 hours 
injection were included in the analysis, excluding the mouse (Figure 3.13) that showed 
the opposite trend. As seen from Figure 3.16 (a), a statistically significant (p < 0.05) 
difference is seen in the lactate levels pre and 24 hours post CA4P injection, in both the 
1X and 5X reconstructions.  
On the other hand, no statistical significance is seen (p > 0.05) between the 1X 
and 5X reconstructions, both pre and post injection, indicating high fidelity between the 
reference and accelerated datasets. When all five mice were included in the analysis, no 
statistical significance (p > 0.05) in the paired t-test was observed between the measured 
tumor lactate levels, pre and 24 hours post administration of CA4P as illustrated in Figure 
3.16 (b). However, the reconstruction accuracy between the 1X and 5X was still 
preserved with p > 0.05. 
All five mice were included for analysis in the control cohort. As seen in Figure 
3.16 (c), no statistically significant differences (p > 0.05) were found in the tumor lactate 
levels prior to and 24 hours after the injection of dextrose, as expected. Similarly, the 1X 
and 5X reconstructions were found to be statistically similar (p > 0.05), indicating high 
fidelity and negligible loss of information between the reference and accelerated 
reconstructions. 
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Figure 3.16: Statistical analysis on the CA4P and control cohorts (* indicates p < 0.05). 
(a) The CA4P cohort considering n = 4. Statistical significance found in measured lactate 
levels measured prior to and 24 hours post CA4P injection. (b) The CA4P cohort 
considering n = 5. No statistical significance found between pre and post tumor lactate 
integrated intensities. (c) The control cohort considering n = 5. No statistical significance 
found in tumor lactate pre and post dextrose injection. P > 0.05 between all 1X and 5X 
datasets. 
 
3.3   Discussion & Conclusions 
A CS accelerated lactate-selective MRSI pulse sequence was implemented in the 
Bruker 7 T ParaVision 5.1 environment to facilitate fast MRSI acquisitions of lactate in 
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the preclinical setting. The developed sequence achieved the prospective pseudo-random 
undersampling of the k-space ‘on the fly’ to facilitate CS acquisitions and reconstruction. 
The lactate-selective CS-MRSI sequence achieved high-speed mapping of the lactate 
peak both in vitro and in vivo in solid tumors and could potentially save 80% of the 
acquisition time.  
As previously discussed, lactate is a key player in cancer. The increased glucose 
uptake by cancer cells as compared to normal tissues can be exploited for tumor 
diagnostics, anti-cancer therapy, and in the detection of metastasis using 2-[18F]Fluoro-2-
deoxyglucose positron emission tomography (FDG-PET) [127]. Both hexokinase activity 
and glucose transporter expression tend to regulate the update of FDG in cells [127, 128]. 
FDG-PET thus enables a non-invasive visualization of the Warburg effect, which is a 
fundamental property of neoplasia [128], and has been widely utilized in oncology as a 
staging/restaging tool and biomarker of cancer progression and prognosis. However, this 
technique does have its pitfalls and is not able to capture glucose activity in all types of 
cancers, such as those of the prostate, pancreas, and liver [127]. Other concerns like the 
presence of a strong background signal, inability of the probe to sufficiently perfuse the 
tumor, and efflux of FDG from certain types of cancer cells may hinder the imaging 
process [127].  
The ability to directly measure the lactate distribution in solid tumors can prove to 
be significantly beneficial as this metabolite is a key marker of altered metabolism, 
possible malignancy, and tumor hypoxia. As previously discussed, tumor metastasis and 
recurrence have been linked to elevated lactate concentrations, while variations during 
radiotherapy and treatment can provide insights into the efficacy of a particular 
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therapeutic strategy. While various MRI sequences are capable of measuring tumor 
characteristics such as the perfusion, apparent diffusion coefficient (ADC), and pO2, 
MRSI is the only technique that can map the spatial heterogeneity of lactate in cancer. 
The developed 1H lactate-CS-MRSI sequence offers the possibility of employing fast 
non-invasive lactate imaging as a powerful prognostic marker in the clinic. 
Hyperpolarized 13C MRSI is currently the only other competing technique for [1-
13C] lactate measurements [129-131]. Hyperpolarization offers a 10,000 – 100,000 fold 
increase in the signal intensity [132] and is useful for capturing the pathways of 
endogenous biomolecules [129, 130] upon intravenous injection of the hyperpolarized 
solution that is generated external to the subject. Various acceleration strategies have 
been applied to 13C MRSI [15] (including CS, as reviewed in detail in Chapter 2 of the 
thesis) as the rapid enhancement decay, determined by the T1 of the agent injected (~30 – 
60 s for the agents considered to date [15]), necessitates a rapid acquisition of the data 
following dissolution. This also places a restriction on the type of compounds that can be 
hyperpolarized as the rate of signal relaxation must be slow enough to enable in vivo 
administration and subsequent imaging of metabolism. Other regulatory aspects like the 
integrity of the agent also need to be taken into consideration [15]. The other main 
challenge is the clinical translation of 13C MRI/MRSI due to the need for additional 
hardware, specialized equipment for a sterile preparation of the agent, rapid 
administration of the agent to the patient, and routine quality control checks [133]. 
Human trials have been few [133] and the above mentioned challenges still need to be 
addressed for safe routine clinical scans. Under these circumstances, the developed 1H 
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lactate-CS-MRSI sequence could potentially be beneficial for a regular assessment of 
lactate changes in the clinic, particularly to assess and personalize therapeutic outcomes. 
The later section of this chapter demonstrated the application of the lactate-CS-
MRSI sequence in evaluating changes in lactate levels in response to therapy using 
CA4P. The sequence was used to monitor baseline lactate levels and subsequent changes 
24 hours post the injection of the prodrug. The CS reconstructions maintained high 
fidelity with the 1X reference even at 80% undersampling. Four of the five tumor mice in 
the cohort showed a decrease in the total integrated intensity of lactate within the tumor 
volume when measured 24 hours after CA4P injection, while one mouse from the cohort 
showed a tumor lactate increase 24 hours post CA4P administration. This study 
demonstrated, for the first time, a reduction in lactate levels of H1975 tumors 24 hours 
following a vascular targeting agent, CA4P. To the best of my knowledge, 1H MRSI 
measurement of lactate changes upon CA4P administration has not been documented in 
the literature to date.  
The initial hypothesis for this study was that an increase in tumor lactate levels 
would be observed upon treatment using CA4P. This is based on the fact that CA4P-
induced vascular shutdown would lead to more hypoxia or acidosis, causing higher 
glycolysis rates to produce more lactate. A poorly perfused tumor vasculature may also 
not be able to clear the accumulated lactate efficiently. However, previous studies have 
demonstrated an improvement in the tumor pO2 and vascular perfusion 24 hours post 
CA4P administration, suggesting that there is recovery in the vasculature particularly in 
the rim of the tumor [118, 121, 125]. This would potentially result in improved blood 
flow and lead to either an increase in lactate clearance or decreased production of lactate, 
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or possibly both. This might explain why a decrease in tumor lactate levels was measured 
24 hours post injection of CA4P. Previous studies have also observed that there is 
heterogeneity in the restoration of perfusion within the tumor, with lower lactate levels 
detected in the better perfused regions [125]. The study by Bohndiek et al demonstrated a 
34% decrease in the rate constant corresponding to 13C hyperpolarized labeled flux 
between [1-13C] pyruvate and lactate [125] 6 hours after CA4P injection, and continued 
to be at that lower level even after 24 hours. However, no significant change in lactate 
concentrations in tumor extracts was detected 24 hours later in this study [125]. Other 
VDAs like ZD6126 have also been employed to probe tumor dynamics [134] using a 
MQC spectral editing sequence wherein no significant change in lactate was found in 
response to the prodrug. Another aspect to take into consideration would be the type of 
tumor being investigated as response to targeting agents and therapeutics may be varied 
among different types of solid tumors.  
In conclusion, fast lactate MRSI was implemented in the preclinical setting with a 
reduction in the acquisition time by up to 80% in vivo. This study also offered a first 
insight into H1975 tumor lactate dynamics in response to treatment using CA4P, wherein 
a decrease in tumor lactate levels was measured 24 hours after administration of the 
prodrug. Future studies could further investigate the CA4P-induced dynamics of tumor 
lactate metabolism in different types of cancers in vivo using MRSI. 
(Note: Certain sections of Chapter 3 are based on the paper – “Compressed Sensing 
Accelerated MR Spectroscopic Imaging of Lactate”, R. Vidya Shankar, S. Agarwal, and 
V. D. Kodibagkar, in preparation for submission to Magnetic Resonance in Medicine for 
review.)  
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CHAPTER 4 
2D CS-MRSI OF THE PEDIATRIC BRAIN 
 
The advantages offered by MRSI in the non-invasive, quantitative mapping of 
important biomarkers have been documented in Chapters 1, 2, and 3 of this dissertation. 
The objective of this study was to retrospectively evaluate the feasibility of scan time 
reduction using compressed sensing (CS) based MRSI in pediatric patients undergoing 
routine brain exams. 
4.1   Background 
Various MRI sequences are routinely employed in pediatric neuroimaging studies 
for longitudinal investigations of brain development and function in children. 
Spectroscopic imaging techniques like single voxel spectroscopy (SVS) and MRSI/CSI 
can be employed to assess the concentrations of various metabolites in the pediatric brain. 
For e.g. rapid neurochemical changes in brain structure and content have been observed 
at various stages of brain development [135, 136], with an increase in NAA, creatine, and 
glutamate accompanied with a decrease in the concentrations of choline and myo-inositol 
(mI) [137]. Vital biochemical information can be extracted in numerous pathological 
conditions and diseases such as in neuro oncology and brain tumors [138-143], 
neurofibromatosis [144], tuberous sclerosis [145], epilepsy and other related seizures 
[146], neurodegenerative, neuropsychiatric, and mitochondrial disorders [135, 137, 143], 
and in the evaluation of hypoxia/ischemia and stroke in the pediatric brain [147]. 
 The basic principles of SVS and MRSI along with their respective 
merits/demerits have previously been discussed in Chapters 1 and 2 and will not be 
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elaborated here. The long scan times encountered in MRSI are not desirable when 
imaging pediatric patients as children are more likely to move or not cooperate during the 
examination window. This could also have added implications like increasing the 
sedation time for patients under anesthesia, such as in infants and in the elderly. Thus, it 
is crucial to devise and implement fast imaging techniques for the benefit of the pediatric 
patient population.  
However, very few studies have sought to investigate and validate the feasibility 
of fast imaging techniques in pediatric patients in both MRI and MRSI [148-153]. The 
fast MRSI study by Kim et al using dual band RF pulses and a spiral k-space readout 
focused on the rapid extraction of metabolic profiles from the corticospinal tract in the 
pediatric brain [148], while the study in children by Vasanawala et al investigated the 
application of fast CS-MRI combined with parallel imaging in various anatomies like the 
abdomen, cardiac, and knee [149]. The clinical performance of rapid acquisition using 
compressed sensing (CS) and parallel imaging in contrast enhanced abdominal pediatric 
MRI has been assessed by Zhang et al and Cheng et al [152, 153]. A fast pediatric 
cardiac study by Hsiao et al focused on the application of parallel imaging and CS for the 
evaluation of ventricular volume and blood flow in volumetric phase contrast MRI [150]. 
In all the above mentioned studies, a significant reduction in the acquisition time was 
achieved with preservation of anatomic detail, and spatial and spectroscopic image 
quality.      
The objective of this study was to test the application of CS accelerated MRSI in 
pediatric patients undergoing routine MRI scans for various brain-related concerns. The 
theory and principles underlying CS have been discussed in previous chapters and will 
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not be elaborated here. The retrospective application of CS-MRSI is evaluated in both 
healthy brain tissue and in a few tumor cases for accelerations up to five-fold, with a 
quantitative evaluation of the accuracy and fidelity of the reconstructed spectra in 
comparison with the fully-sampled 1X reference MRSI datasets.   
 
4.2   Materials and Methods 
This study was approved by the local institutional review board and was 
compliant with the Health Insurance Portability and Accountability Act (HIPAA). 
Informed consent was obtained for acquiring the MRSI data, wherein a stock 
spectroscopic imaging pulse sequence provided by the MRI manufacturer was employed. 
The retrospective evaluation of 2D 1H CS accelerated MRSI was performed on 20 
pediatric brain cases, which included 11 male and 9 female patients in the age range 3 
days to 16 years. Tables B.1 and B.2 (Appendix B) summarize the demographic details 
and various MRI/MRSI parameters related to the patient group under consideration. 
 
4.2.1 MRSI Data Acquisition and Undersampling 
All MRSI data was acquired on a Philips 3 T Ingenia MRI scanner using a 
standard point resolved spectroscopy (PRESS) based MRSI pulse sequence. A 13-
channel head coil array was employed for all experiments. Initial studies involved testing 
the CS-MRSI reconstruction algorithm on phantom (metabolite solution -12 mM NAA, 
10 mM creatine, 3 mM choline) and volunteer MRSI datasets. In the patient studies, 
general anesthesia was administered to the patients for their routine brain MRI exam. 
Fully sampled MRSI data was collected on patients in the age range 3 days - 16 years 
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with the following acquisition parameters: TE/TR = 46/1500 ms, 16x16x2048 grid, 10 
mm slice thickness, 1 average, total acquisition time for the fully sampled 1X reference 
dataset = 9 min. The variable density sampling mask for different acceleration factors, 
illustrated in Figure 4.1, was generated as previously described in [70, 71]. The k-space 
was pseudo-randomly undersampled along the phase encode directions to generate 
datasets that represented 2X (50%), 3X (33%), 4X (25%), and 5X (20%) acceleration. 
 
 4.2.2 CS-MRSI Reconstruction 
A custom non-linear iterative reconstruction based on the conjugate gradient 
algorithm was implemented in Matlab (Mathworks Inc., MA) to reconstruct all the 
retrospectively undersampled MRSI datasets. The CS-MRSI reconstruction was 
formulated as a convex optimization problem, which involved minimizing the cost 
function [71], previously detailed in Chapter 3. 
 
4.2.3 Post Processing and Error Metric 
All reconstructed CS-MRSI datasets were subjected to a quantitative comparison 
with the fully sampled 1X reference dataset using the metrics discussed in Chapter 3. In 
each case, the root mean square error (RMSE) metric was used to compute the 
reconstruction error for each individual metabolite (NAA, creatine, choline, and lactate), 
as previously employed in Chapter 3. The RMSE can be interpreted as being equivalent 
to the normalized RMSE (nRMSE) since the range of each dataset was normalized to 
vary from 0 to 1. Standard post-processing steps were applied to all the reconstructed 
MRSI datasets using the jMRUI [111]  software package. Detailed analysis was 
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performed on the voxels located in the region interior to the brain for all the twenty MRSI 
datasets under consideration. A total of 957 voxels were analyzed across all the pediatric 
brain MRSI datasets.  
 
4.2.4 Statistical Analysis 
A voxel-wise 2-tailed paired t-test was performed on the metabolite intensity and 
ratio maps (NAA/Cr, NAA/Cho, and Cho/Cr) from each reconstructed dataset with the 
corresponding 1X reference dataset using the GraphPad Prism (San Diego, CA, USA) 
scientific software. A p-value < 0.05 was considered to be statistically significant and 
indicative of an inaccurate reconstruction. Voxels with a denominator value of zero (lack 
of deterministic fit) in the 1X or accelerated reconstructions were set to zero for the ratio 
calculations. In addition, the fidelity of the reconstructions was assessed by determining 
the magnitude of correlation between the 1X fully sampled reference and the accelerated 
reconstructions using the Origin® 8.1 software package. Correlation graphs were 
generated for individual mean metabolite intensities collated from all twenty datasets and 
evaluated against the 1X fully sampled reference as a function of acceleration. The 
accelerated reconstructions were considered quantitatively equivalent to the 1X reference 
if the magnitude of coherence was close to one, using a 95% confidence interval. 
 
4.3   Results 
The retrospective evaluation of CS-MRSI was initially conducted on phantom and 
human volunteer MRSI datasets from the 3 T Philips Ingenia MRI scanner. Variable 
density undersampling masks for acceleration factors 2X – 5X that were simulated in 
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MatlabTM are depicted in Figure 4.1. Figures 4.2 and 4.3 depict the results from the 
phantom experiments, wherein mean metabolite intensities are accurately reconstructed 
up to five-fold acceleration, with high spectral fidelity and negligible information loss. 
Figure 4.3 shows the nRMSEs for each individual metabolite and for the full spectrum. 
The normalized metabolite RMSEs remain below 3% up to 5X for each individual 
metabolite, while the nRMSE for the entire spectrum is slightly above 1% at five-fold 
acceleration. 
 
Figure 4.1 Variable density under-sampling masks simulated in MatlabTM for various 
acceleration factors – 16x 16 matrix (total 256 samples 1X). 
 
Figure 4.2 Metabolite maps of NAA (12 mM), creatine (10 mM), and choline (3mM) at 
acceleration factors 1X, 2X, and 5X (16x16x2048 grid, TR/TE = 2000/46 ms, 20 mm 
slice thickness, 1 average). 
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Figure 4.3 The nRMSEs for the phantom dataset at acceleration factors 2X – 5X. (a) the 
full spectrum, (b) NAA, (c) Creatine, and (d) Choline. 
 
A retrospective evaluation of CS-MRSI was also conducted in 3 normal human 
volunteers, with results depicted in Figures 4.4 and 4.5. This study was approved by the 
local institutional review board and informed consent was obtained for acquiring the 
MRSI data. Figure 4.4 depicts select voxels from a volunteer brain MRSI dataset, with 
spectral fidelity maintained up to 5X.  
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Figure 4.4 Spectra from select voxels of a volunteer MRSI dataset. MRSI scan 
parameters: 16x16x2048 matrix, TR/TE = 1500/46 ms, 1 average, 1 cm slice thickness, 
FOV 24 x 24 cm2, total scan time for the 1X = 9 min. The y-axis limits are from -0.1 to 1 
for all illustrated spectra.  
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Figure 4.5 Mean nRMSEs ± standard deviations for the 3 volunteer MRSI datasets for 
(a) the full spectrum, (b) NAA, (c) creatine, and (d) choline. 
 
Figure 4.5 shows the mean normalized RMSEs for the 3 volunteers at 2X-5X 
accelerations. The nRMSE at 5X for the full spectrum is (1.6 ± 0.26) %, while that for the 
individual metabolites is (2.96 ± 0.39) % for NAA, (2.6 ± 0.45) % for creatine, and (2.49 
± 0.34) % for choline. The reconstruction error remains below 3.5% up to 5X when 
considering individual metabolites, with a low and consistent standard deviation across 
the 3 volunteers for accelerations 2X – 5X. Mean metabolite ratios NAA/Cr, Cho/NAA, 
and Cho/Cr ± standard deviations have been collated in Table 4.1 for the three volunteers. 
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Table 4.1 Mean metabolite ratios ± standard deviations for the 3 volunteer MRSI datasets 
for 1X – 5X acceleration factors. (NAA: N-acetylaspartate, Cr: creatine, Cho: choline, M: 
male, F: female, SD: standard deviation) 
Volunteer NAA/Cr 
(mean ± SD) 
Cho/NAA 
(mean ± SD) 
Cho/Cr 
(mean ± SD) 
 
 
1 
(M) 
1X 2.58 ± 1.04 0.43 ± 0.14 0.98 ± 0.17 
2X 2.61 ± 1.11 0.43 ± 0. 16 0.98 ± 0.16 
3X 2.62 ± 1.07 0.43 ± 0.14 0.99 ± 0.15 
4X 2.73 ± 1.08 0.47 ± 0.15 0.99 ± 0.15 
5X 2.79 ± 1.07 0.49 ± 0.14 1.1 ± 0.15 
 
 
2 
(M) 
1X 2.46 ± 1.1 0.46 ± 0.16 1 ± 0.22 
2X 2.49 ± 1.16 0.46 ± 0.17 1 ± 0.23 
3X 2.44 ± 1.15 0.47 ± 0.16 1 ± 0.19 
4X 2.5 ± 1.23 0.47 ± 0.17 1.03 ± 0.2 
5X 2.52 ± 1.26 0.48 ± 0.16 1.2 ± 0.19 
 
 
3 
(F) 
1X 2.44 ± 0.77 0.39 ± 0.09 0.91 ± 0.16 
2X 2.44 ± 0.84 0.4 ± 0.1 0.99 ± 0.14 
3X 2.5 ± 0.79  0.45 ± 0.09 1.02 ± 0.16 
4X 2.4 ± 0.69 0.48 ± 1.05 1.15 ± 0.14 
5X 2.31 ± 0.69 058 ± 0.09 1.17 ± 0.15 
 
The retrospective evaluation of CS-MRSI was subsequently performed on 
pediatric MRSI datasets. Demographics of the pediatric patients scanned, the reason for 
MRI, and metabolite ratios from MRSI have been collated in Tables B.1 and B.2 
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(Appendix B). The patient population consisted of 11 male and 9 female patients that 
included healthy, tumor (also post-surgery) and non-tumor cases, and a few with brain 
development concerns. The corresponding metabolite ratios from MRSI for all 
accelerations 1X – 5X have also been documented, with expected variations seen in 
normal and tumor voxels. Table B.1 lists all parameters from the non-tumor cases, while 
Table B.2 has parameters corresponding to the patients with brain tumors. 
Figures 4.6 and 4.7 depict the MRSI reconstruction results for various 
acceleration factors from a nine year old female patient scanned for seizures (case 6 in 
Table B.1). Figure 4.6 shows the PRESS volume of interest (VOI) selected for MRSI 
overlaid on the T1 anatomical scout from MRI, with the corresponding spectroscopic 
imaging grids for acceleration factors 2X - 5X. The CS-MRSI reconstructions displayed 
spatial distributions that were very similar to that of the 1X reference dataset, with no 
spurious signals outside the selected VOI. An expanded view of the 1X and 5X 
spectroscopic grids is depicted in Figure 4.7.  
Within the VOI, select voxels were examined to assess the reconstruction quality 
of individual spectra. Figure 4.8 highlights the spectra from two voxels (blue and green) 
in the VOI and one (red) located exterior to but close to the periphery of the brain. The 
CS reconstructions preserve the line shape of the each individual metabolite, with good 
agreement observed in the peak amplitudes for various accelerations up to 5X. Gradual 
smoothing of the spectra can be seen with increasing acceleration, which can be 
attributed to the denoising effects of the wavelet and total variation terms in the CS 
reconstruction. The difference spectra computed at each acceleration factor also indicate 
a high fidelity in the CS reconstructions with respect to the 1X fully sampled reference. 
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The corresponding metabolite maps (obtained after spectral fitting of the peak amplitudes 
in jMRUI) of NAA, creatine, and choline have been illustrated in Figure 4.9 for the 1X-
5X MRSI datasets. Similar spatial distributions can be observed with increasing 
acceleration for each metabolite. 
 
Figure 4.6 MRSI data from a nine year old female patient scanned for seizures and 
diagnosed with a 2x2 cm2 arachnoid cyst in the anterior right temporal lobe. The figure 
depicts the anatomical scout MRI with the PRESS VOI, along with the spectroscopic 
imaging grids corresponding to the VOI for acceleration factors 2X – 5X. 
 
 Figure 4.10 displays the metabolite maps of NAA, creatine, choline, and 
lactate for a pediatric patient diagnosed with a brain tumor. Figure 4.10 depicts the fully 
sampled and accelerated metabolite maps for a MRSI dataset collected from a 10 year old 
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male diagnosed with two intra-axial masses of metastatic Ewing’s sarcoma, one each in 
the right temporal and right parietal lobes (case 1 listed in Table B.2). In this case, the 
spatial distribution of all metabolic profiles is accurately preserved for acceleration 
factors up to 5X, including the voxels covering the tumors. Distinct variations can be 
observed between the metabolite distributions in the normal and cancerous tissue regions, 
as expected. The presence of lactate, an important marker of anaerobic glycolysis in solid 
tumors, is readily seen in the lesion. Both the spatial spread and spectral line profile of 
the lactate peak maintains high fidelity with the 1X for CS reconstructions 2X – 5X. 
 
Figure 4.7 An expanded view of the 1X and 5X MRSI grids from Figure 4.6. 
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Figure 4.8 Select voxels in blue, green, and red from the representative MRSI dataset in 
Figure 4.6 for acceleration factors 2X – 5X, 7X, and 10X. The major metabolite peaks 
NAA, creatine, and choline seen in normal brain voxels are depicted, along with a select 
voxel located outside but close to the periphery of the brain. The y-axis limits are from -
0.3 to 1 for all illustrated spectra. The CS-MRSI reconstructions display high accuracy 
even at an acceleration of five. 
 
Figures 4.11 and 4.12 show a few select reconstructed voxels from two tumor 
MRSI datasets. The MRSI dataset illustrated in Figure 4.12 is from a 1.5 year old male 
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patient with a large contrast enhancing lesion in the right posterior lateral basal 
ganglia/thalamus, as detected by MRI (case 2 from Table B.2). Figure 4.11 shows spectra 
corresponding to the dataset in Figure 4.10 for the original and CS-accelerated MRSI 
data. The reconstruction quality was evaluated for one voxel each selected from the 
normal and tumor regions. The distinct spectral profiles of the metabolites that help 
distinguish between normal and cancerous tissue have been accurately maintained for the 
CS-MRSI datasets 2X-5X, as compared to the 1X reference. The same trend is observed 
in the second brain tumor spectra depicted in Figure 4.12, with faithful CS 
reconstructions even at higher undersampling factors (up to 5X), and evident differences 
in the metabolite peak amplitudes in the illustrated normal and tumor tissue voxels.  
 
Figure 4.9 Metabolite maps showing the distribution of NAA, creatine, and choline for 
acceleration factors 1X - 5X in a nine year old female patient scanned for seizures. The 
mean metabolite ratios for the 1X are given by NAA/Cr = 2.4 ± 1.17, Cho/Cr = 1.0 ± 
0.25, and Cho/NAA = 0.47 ± 0.18. The mean metabolite ratios for the 5X are given by 
NAA/Cr = 2.83 ± 2.26, Cho/Cr = 0.92 ± 0.2, and Cho/NAA = 0.43 ± 0.19. 
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The RMSE metric was employed to quantify the error in reconstruction (2X - 5X, 
7X, 10X) for all 20 pediatric CS-MRSI datasets and is depicted in Figure 4.13. Figures 
4.13 (a) - (d) show the individual metabolite RMSEs for NAA, lactate, creatine, and 
choline respectively. Figure 4.13 (e) shows the RMSE for the entire spectrum. In each 
dataset, the error increases with increasing acceleration as expected, but does not exceed 
3% at 5X for the full spectrum in any of the reconstructed datasets. The RMSEs for the 
individual metabolites remained below 5% even at an acceleration of 5X, as illustrated in 
Figure 4.13 (a) – (d).  
 
Figure 4.10 Representative metabolite maps of NAA, creatine, choline, and lactate for 
acceleration factors 1X – 5X. MRSI data was collected from an 11 year old male patient 
diagnosed with two intra-axial masses of metastatic Ewing’s sarcoma, one in the right 
temporal lobe, and the other in the right parietal lobe. High lactate distribution was found 
in the tumor region with very low concentrations of the other major brain metabolites.  
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Figure 4.11 Spectra from select voxels of the pediatric brain tumor MRSI dataset 
previously depicted in Figure 4.10. A huge lactate peak is seen in the tumor voxel 
indicated in red. The normal and tumor voxels also show variations in the peak 
amplitudes of choline and NAA. The y-axis limits are from -0.3 to 1 for all illustrated 
spectra. All accelerations 2X – 5X show good fidelity with the 1X reference. 
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Figure 4.12 Spectra from select voxels of a second pediatric brain tumor MRSI dataset. 
Lactate is seen in the tumor voxel indicated in red. The normal and tumor voxels also 
show variations in the peak amplitude of choline, with higher concentration seen in the 
tumor as expected. The y-axis limits are from -0.3 to 1 for all illustrated spectra. All 
accelerations 2X – 5X show good fidelity with the 1X reference. 
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Figure 4.13 Normalized RMSEs of all 20 pediatric MRSI datasets that were evaluated 
using CS undersampling and reconstruction for up to 90% reduction in the scan time. 
Individual metabolite RMSEs are depicted in (a)–(d), full spectrum in (e). The RMSE 
increases with higher acceleration and stays below 5% when computed for the individual 
metabolites, and overall below 3% (when considering the complete spectrum) up to 5X.  
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Figure 4.14 Correlation plots (1X vs 2X – 5X) of mean NAA intensities from the 20 
pediatric brain MRSI datasets. 
 
 
Figure 4.15 Correlation plots (1X vs 2X – 5X) of mean creatine intensities from the 20 
pediatric brain MRSI datasets. 
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Figure 4.16 Correlation plots (1X vs 2X – 5X) of mean choline intensities from the 20 
pediatric brain MRSI datasets. 
  
Correlation graphs for the metabolites NAA, creatine, and choline are depicted in 
Figures 4.14, 4.15, and 4.16 respectively. Mean metabolite intensities were computed for 
each of the 20 pediatric MRSI datasets and plotted against the corresponding 1X 
reference metabolite intensities as a function of acceleration (2X – 5X). As seen from the 
plots, a very high magnitude of correlation (with the slope close to one in each case) 
exists between the 1X and 2X-5X reconstructions, for each individual metabolite within a 
95% confidence interval. Although deviations from the gold standard increase with 
increasing acceleration, no metabolite data point lies outside the confidence interval 
represented by the ellipse, with very few instances in which the points are located close to 
or at the boundary of the ellipse. This indicates that even individual metabolite intensities 
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in the CS-MRSI reconstructions maintained high fidelity with the 1X fully sampled 
reference, for acceleration factors 2X – 5X, with insignificant loss of information.  
Tables B.1 and B.2 show the means ± standard deviations of three different 
metabolite ratios for acceleration factors of 1X – 5X for the each individual pediatric 
MRSI dataset. The 20 datasets that were analyzed were divided into two main categories, 
namely, tumor cases (6, includes resected tumors) and non-tumor (14) datasets. Only 
voxels from the interior of the brain (corresponding to the selected VOI during imaging) 
were chosen and analyzed in both the above mentioned categories. In both groups, the 
mean metabolite ratios for accelerations 2X – 5X are comparable and have a strong 
correlation with the 1X values, with no statistically significant differences seen (p > 
0.05). The lack of any significant differences/variations indicates that the accelerated 
reconstructions of these critical biomarkers in both tumor and non-tumor datasets is 
faithfully preserved and comparable to the 1X even at an acceleration factor of five. 
 
4.4   Discussion & Conclusions 
In this study, the in vivo application of compressed sensing to pediatric MRSI 
demonstrates that a quantitatively accurate reconstruction can be achieved by sampling 
only 20% of the k-space, thus, significantly reducing the scan time in spectroscopic 
imaging. This will facilitate the integration of MRSI in clinical protocols, leading to a 
more comprehensive evaluation of metabolite maps that contain vital prognostic and 
diagnostic information. The inclusion of MRSI scans can prove critical in children as one 
can monitor the spatial changes in these important biomarkers, particularly in the 
developing and diseased brain. It could also help identify specific markers in common 
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childhood cancers of the brain and central nervous system that have an incidence of 5.3 
per 100,000 in the 0 – 19 years age group [154].  
The CS accelerated reconstructions maintained high spectral accuracy for up to 
80% under sampling for each of the 20 pediatric brain MRSI datasets that were analyzed, 
with overall reconstruction errors that were lower than 3% (and individual metabolite 
errors that were less than 5%). This clearly demonstrates the feasibility and repeatability 
of our approach to produce consistently faithful results in a varied group of clinical MRSI 
datasets. The previous study from our group focused on the evaluation of the in house 
developed reconstruction algorithm in adult patients, including both normal and tumor 
cases [71]. In the current study, we wanted to further validate the reproducibility of our 
approach in pediatric patients as only a handful of studies have investigated the 
possibility of fast imaging in pediatric MRI and MRSI datasets [148-153], as previously 
discussed. This study, thus, presents a more detailed analysis of the application of CS-
MRSI in the pediatric brain.    
Apart from the qualitative inspection of the metabolite maps and spectra, the CS-
MRSI reconstructions for various accelerations and the reference 1X dataset are 
statistically comparable, as indicated by the p-values generated from a series of voxel-
wise paired t-tests. Derived parameters, like metabolite ratios, are also accurately 
reconstructed up to an acceleration factor of five. A p-value threshold of 0.05 was 
considered optimal as in this study we were testing for non-significant differences and 
assessing spectral and spatial fidelity in the reconstruction. A p-value < 0.05 was 
considered to indicate a statistically significant difference between the reference and 
accelerated dataset, and thus, suggestive of a failed reconstruction. 
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The reconstructions at 7X and 10X were found to be statistically different from 
the 1X for most metabolite ratios, indicating increased deviation and higher 
reconstruction errors. Our ongoing work focuses on identifying the optimal acceleration 
factor between 5X and 10X that would result in a statistically comparable reconstruction 
for all considered datasets. Another area that requires further investigation is the selection 
of an optimal undersampling mask that produces the least errors and is tailored to the CS-
MRSI reconstruction at hand, particularly at higher accelerations (> 4X). A bad 
undersampling mask, as previously discussed by Lustig et al [70] and in more recent 
studies [155, 156], might result in a poor reconstruction. 
Furthermore, certain user-dependent factors like inconsistent post processing and 
spectral fitting of the MRSI datasets can also contribute to differences between the 
original and undersampled datasets. Increased deviations (in either direction) in the 
metabolite peak amplitudes have been observed with higher under sampling. Various 
contributing factors to the reconstruction error include the VOI that was selected, size of 
the MRSI grid, SNR of the original k-space data acquired, along with a sub-optimal 
choice of regularization parameters for the reconstruction algorithm. The errors can be 
particularly significant when there is a huge SNR penalty to begin with in MRSI (for e.g. 
when imaging difficult regions), causing the CS reconstruction to break down.  
The metabolic changes measured by MRS(I) can aid in the characterization of 
numerous neurological disorders. It is critical to estimate the sensitivity and specificity of 
changes in metabolite concentrations associated with each disease prior to the application 
of any acceleration technique. For e.g. MRS(I) has been found to be highly sensitive and 
specific to identifying metabolic changes in Alzheimer’s disease and mild cognitive 
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impairment, wherein NAA, choline, and myo-inositol (mI)/creatine ratios are assessed 
[157-159]. In a clinical study by Moats et al [158], a receiver operating characteristic 
(ROC) of mI/Cr and NAA/Cr ratios was employed to make a diagnosis. A decrease in 
NAA concentration has direct correlation with the severity of neuropathological findings 
[159] along with an increase in mI levels, establishing the NAA/mI index as a sensitive 
marker of abnormalities in cognitive function. In epileptic seizures, MRS(I) has been 
found to be highly sensitive to a decrease in NAA levels in the epileptogenic focus, even 
when no abnormality was detected in the accompanying MR scans in a majority of 
patients [160]. Cerebral lactate has also been detected in patients with seizures as 
compared to the control group [160, 161].  
MRS(I) can identify marked NAA reduction and lactate increase in stoke/cerebral 
ischemia, while inconsistent changes have been measured in the peaks from choline and 
creatine [162]. MRS(I) has also proven beneficial in differentiating brain tumors from 
non-neoplastic lesions (72% sensitivity, 92% specificity [163]), and evaluating low grade 
vs high grade gliomas (93% sensitivity, 60% specificity [164]). Various pediatric specific 
neurological abnormalities like inherited metabolic disorders, hypoxia ischemia, and 
traumatic brain injury (TBI) can be assessed with 1H spectroscopy [165]. In all the 
discussed neurological conditions, MRS(I) shows high sensitivity and specificity to the 
detection of major metabolites like NAA, creatine, and choline. Other metabolites such 
glutamate, glutamine, GABA, alanine, and lactate are in a majority of cases not reliably 
detected owing to their low concentration and considerable spectral overlap with stronger 
resonances in the MRS spectrum. In such instances, specialized pulse sequences that 
permit selective excitation of these hard to detect metabolites [106, 107, 166-171] can be 
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combined with acceleration techniques to increase the sensitivity and specificity of 
MRSI. For e.g. the lactate specific CS-MRSI sequence that was discussed in Chapter 3 
could prove very useful in the enhanced detection of lactate metabolism in solid tumors. 
Specialized editing sequences have also been developed for the improved detection of 
metabolites such as γ-Aminobutyric acid (GABA) [169, 171], 2-hydroxyglutarate (2HG) 
[166, 167], glutamine and glutamate [170], and glycine [168]. These sequences can be 
combined with fast acquisition strategies like CS for a precise, high-speed detection of 
these smaller biomarkers.    
   The retrospective application of CS under sampling to MRSI was the main 
limitation of this study. However, we believe our work is an important step in the 
validation of CS-MRSI reconstructions in pediatric brain datasets, with future studies 
focusing on the prospective implementation.   Another limitation of the study was that we 
did not test CS in conjunction with 3D MRSI datasets, which cannot be acquired in 
patients due to the prohibitive scan time. For e.g. considering one signal average and a 
TR of 1 s, a 16x16x16 spectroscopic grid would require the acquisition of 4096 signals, 
leading to a total scan time of approximately 1 hour and 8 mins, which is prohibitive 
where patients are under general anesthesia. 
In conclusion, it has been demonstrated that 2D MRSI can be accelerated by 80% 
using compressed sensing in the pediatric clinical setting, with minimal loss in spectral 
fidelity and accuracy in metabolite quantification.  This methodological advancement has 
the potential to increase the utility of MRSI in routine clinical evaluation of brain 
morphology and function, as well as in other organs.  
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(Note: Chapter 4 is based on the paper – R. Vidya Shankar, H. H. Hu, J. C. Chang, and 
V. D. Kodibagkar, “2D MR Spectroscopic Imaging of the Pediatric Brain Using 
Compressed Sensing”, in preparation for submission to Radiology.) 
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CHAPTER 5 
CLINICAL IMPLEMENTATION OF CS-MRSI & OPTIMIZATION OF CS 
UNDERSAMPLING 
 
5.1   Prospective CS-MRSI 
The objective of this study was to implement CS acquisitions prospectively on a 
GE Discovery 3 T clinical MRI scanner and assess the fidelity of the CS-MRSI 
reconstructions. Pseudo-random undersampling masks [70] designed to skip phase 
encodes, corresponding to acceleration factors 2X, 3X, 4X, and 5X were incorporated 
into the GE ‘presscsi’ pulse sequence via the EPIC programming environment. The CS-
MRSI sequence was tested on the ‘braino’ metabolite phantom (12.5 mM NAA, 10 mM 
creatine, 3 mM choline)  by prospectively acquiring the 1X – 5X MRSI datasets, with the 
following acquisition parameters: 16x16x2048 grid, TE/TR = 144/2000 ms, 1 average, 10 
mm slice thickness, total acquisition time 8 min 40 s (1X), 4 min 20 s (2X), 2 min 54 s 
(3X), 2 min 20 s (4X), and 1 min 44 s (5X). All CS-MRSI datasets were reconstructed 
and post processed using the procedures outlined previously in Chapters 3 and 4 to 
generate the final metabolite maps at each acceleration factor.  
Figure 5.1 shows the acquired k-space maps of the 1X reference and 2X – 5X CS-
MRSI datasets as an illustration of the prospective undersampling on the scanner. The 
metabolite maps of NAA, creatine, and choline for each acceleration factor are illustrated 
in Figure 5.2. As seen from the figure, the integrated metabolite intensities maintain high 
fidelity with the 1X reference, with negligible loss of information. No statistically 
significant differences were seen between the 1X reference and CS-MRSI reconstructions 
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for up to 80% undersampling. A decrease in the peak amplitudes was observed with 
increasing acceleration; this can be attributed to a sub-optimal choice of parameters in the 
iterative reconstruction algorithm along with slight differences in the prospectively 
acquired signal intensities at each acceleration factor as compared to the 1X reference. 
The normalized RMSEs at all acceleration factors are depicted in Figure 5.3(a), wherein 
the reconstruction error remains below 3.5 % for up to an acceleration of 5X.  
 
Figure 5.1 K-space map (kx, ky, kt=0) from a prospectively under-sampled 2D PRESS-
MRSI dataset (3T, TR/TE= 1200/35 ms, 16X16X1028) acquired on a metabolite 
phantom. 
 
Figure 5.3 (b) lists statistical comparisons between the 1X and accelerated 
datasets. As seen from the table, the p-values indicate a strong correlation between 
accelerations 1X – 4X. The p-values for the 1X vs 5X case are weaker, but not 
statistically different (p > 0.05) from the ground truth. 
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Figure 5.2 GE ‘braino’ metabolite phantom - 16x16x2048 matrix, TE = 144 ms, TR = 
2000ms, 1 average, 10 mm slice thickness, total acquisition time 8 min 40 s (1X). 
Metabolite maps of NAA (12.5 mM), creatine (10 mM), and choline (3 mM) for various 
acceleration factors (2X-5X). 
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Figure 5.3 (a) The normalized RMSEs from the ‘braino’ phantom for acceleration factors 
2X – 5X. (b) Statistical comparisons with the 1X reference dataset.  
 
 
5.2   Optimal Mask for CS-MRSI 
Random undersampling, or pseudo-random undersampling when considering 
MRI/MRSI, is a key CS requirement, as previously discussed in Chapter 2. A random 
selection of sampling locations ensures incoherent aliasing artifacts, which can 
subsequently be removed by signal denoising procedures [70]. A pseudo-random mask 
undersamples the peripheral regions of k-space more as compared to the center. This is 
preferred as most of the signal energy is in the low frequency components that are located 
at the k-space origin.  However, the choice of an optimal sampling mask (along with the 
type of sparsifying transform) is critical for obtaining an accurate reconstruction. Not all 
pseudo-random sampling patterns achieve a sufficient degree of incoherence required in 
CS for accurate signal recovery. The key requirement to determining an optimal mask is 
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to examine the point spread function (PSF), which is a useful tool to measure 
incoherence, as discussed by Lustig et al [70]. Pixels do not display any interference 
when sampling under the Nyquist criterion i.e. the non-diagonal terms of the PSF are 
essentially zero :, <
6=> = 0. Interference between pixels is caused when the Nyquist 
limit is violated, with the emergence of non-zero off-diagonal terms. The degree of 
incoherence can be measured by calculating the maximum value of the side lobe-peak 
ratio (SPR) when undersampling below the Nyquist limit [70]. The sampling pattern at a 
particular acceleration with the least peak interference can be considered a good 
candidate for an optimal mask. 
Various methods have been suggested to identify the optimal mask for a particular 
application in MRI [57, 155, 156, 172, 173]. In the study by Knoll et al, a fully sampled 
template image was employed to formulate the probability density function (PDF) to be 
equal to the normalized k-space power spectrum [155]. This ensured that the locations 
with highest energy in k-space were more likely to be sampled. Approaches by Liu et al 
and Ravishankar et al sought to determine the best mask based on errors in k-space 
following a CS reconstruction [172, 173]. Either an existing sampling pattern was 
modified [173], or one was built from scratch [173] by determining the k-space 
coefficients with the highest reconstruction errors and subsequently sampling that 
location [156]. All the above described approaches have been used to determine an 
optimal mask for CS-MRI. However, there is no literature on finding a mask suited to CS 
accelerated proton MRSI. The following sub-section of this chapter seeks to identify an 
optimal sampling mask at a certain acceleration factor using both in vitro and in vivo 1H 
MRSI data.   
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5.3.1 Methods and Sampling Pattern Design 
Phantom (metabolite solution – 12 mM NAA, 10 mM creatine, 3 mM choline) 
MRSI data was acquired on a Philips 3 T Ingenia scanner with the following scan 
parameters – TR/TE = 1500/48 ms, 16x16x2048 matrix, 1 average, 10 mm slice. 
Acquisition parameters for the corresponding T1 anatomical scout were – TR/TE = 83/7 
ms, 128 x128 matrix, 5 mm slice, 1 average. Four different types of masks were 
evaluated at accelerations 2X – 5X in this study, namely, the low resolution, variable 
density (VD), iterative design, and a priori sampling strategies. The number of k-space 
sampling locations for a 16x16x2048 grid at each acceleration factor are as follows: 128 
(2X), 84 (3X), 64 (4X), 51 (5X), 38 (7X), and 26 (10X). In the low resolution mask, all 
samples at each acceleration factor were placed at the center of k-space. The pseudo-
random undersampling strategy described by Lustig et al [70] that was adopted in 
Chapters 3 and 4 of this dissertation was employed to generate the VD mask. 
In the iterative design approach, the k-space locations with the highest 
reconstruction errors were identified and sampled, as proposed by Liu et al [172]. An 
initial mask ‘M’ containing a certain percentage of samples at the k-space center (derived 
from the probability density function (pdf) employed in the pseudo-random 
undersampling design) was used to retrospectively undersample and reconstruct the test 
MRSI dataset. Subsequently, the k-space location with the highest error was identified 
and that location in the mask ‘M’ was then sampled. This procedure, which is similar to a 
brute-force implementation, was repeated till the mask ‘M’ had enough samples to justify 
the chosen undersampling rate. The a priori mask was derived from the k-space of the 
anatomical reference scout acquired using the same field of view (FOV) as the MRSI 
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dataset. The scout k-space was cropped to match the corresponding MRSI spatial grid 
size (16x16). Intensity thresholding was applied to select the highest energy locations of 
k-space to form the mask at a certain acceleration factor. 
 
5.3.2 Simulation Results 
Figures 5.4 – 5.6 depict the simulation results for the phantom MRSI data. At 2X, 
all four undersampling patterns resulted in quantitatively comparable results, with no 
statistically significant differences between the 1X fully sampled reference and the CS-
MRSI reconstructions corresponding to each type of mask. At 3X, increasing deviations 
from the ground truth were found in the low resolution CS-MRSI reconstructions. 
 
Figure 5.4 Reconstruction (mean integrated intensity) results at 2X and 3X using the 4 
types of masks (* indicates p < 0.05). 
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At the 4X and 5X acceleration factors shown in Figure 5.5, the low resolution CS-
MRSI reconstructions continued to show increasing deviations from the 1X reference. 
The iterative design reconstruction broke down at 4X, whereas both the VD and a priori 
masks maintained statistical similarity (p > 0.05) with the 1X up to five-fold acceleration. 
The reconstruction results at 7X and 10X are illustrated in Figure 5.6, wherein the 
reconstructions from all four masks fail. 
 
Figure 5.5 Reconstruction (mean integrated intensity) results at 4X and 5X using the 4 
types of masks (* indicates p < 0.05). 
 
The normalized RMSEs (nRMSE) from all the reconstructed CS-MRSI datasets 
corresponding to each of the four types of masks at 2X – 5X, 7X, and 10X acceleration 
factors have been depicted in Figures 5.7 and 5.8. Figure 5.7 shows the nRMSE that was 
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computed considering the entire MRSI dataset, while in the Figure 5.8 only the voxels 
containing the phantom were considered when computing the nRMSE. The nRMSEs 
from the phantom dataset are comparable for the low resolution, VD, iterative design and 
a priori undersampling, with no significant differences in the reconstruction error 
between the four sampling designs. These results suggest that the nRMSE might not be 
the best metric to employ when evaluating different undersampling patterns and CS-
MRSI reconstruction accuracy. 
 
Figure 5.6 Reconstruction (mean integrated intensity) results at 7X and 10X using the 4 
types of masks (* indicates p < 0.05). All reconstructions fail at 7X and 10X. 
 
Table 5.1 lists the mean metabolite ratios ± standard deviations for the CS 
reconstructions obtained using the four sampling masks for the phantom MRSI dataset.  
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Figure 5.7 The normalized root mean square errors (nRMSEs) for accelerations 2X - 5X, 
7X, and 10X corresponding to each type of mask. The nRMSE was computed for the 
entire MRSI dataset. (LR- low resolution, VD – variable density) 
 
 
Figure 5.8 The nRMSEs for accelerations 2X - 5X, 7X, and 10X corresponding to each 
type of mask. Only the voxels containing the phantom were considered when computing 
the nRMSE. (LR- low resolution, VD – variable density) 
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Table 5.1 Mean metabolite ratios ± standard deviations for the phantom MRSI dataset 
corresponding to low resolution, VD, iterative design, and a priori undersampling at 1X – 
5X, 7X, and 10X accelerations (*p < 0.05 as compared to the 1X). 
 
(LR – Low Resolution, VD – Variable Density, NAA – N-acetylaspartate, Cr – creatine, 
Cho – choline) 
 
Phantom Dataset LR VD Iterative A priori 
 
 
 
 
NAA/Cr 
(Mean ± SD) 
 
1X 2.48 ± 0.56 2.48 ± 0.56 2.48 ± 0.56 2.48 ± 0.56 
2X 2.37 ± 0.67 2.36 ± 0.70 2.38 ± 0.64 2.43 ± 0.94 
3X 2.21 ± 0.36 (*) 2.36 ± 0.71 2.37 ± 0.73 2.38 ± 0.90 
4X 2.17 ± 0.32 (*) 2.31 ± 0.37 2.42 ± 0.75 2.31 ± 0.40 
5X 2.26 ± 0.37 (*) 2.40 ± 1.05 2.29 ± 0.33 (*) 2.42 ± 0.86 
7X 2.29 ± 0.30 (*) 2.27 ± 0.29 (*) 2.22 ± 0.25 (*) 2.25 ± 0.28 (*) 
10X 2.30 ± 0.38 (*) 2.26 ± 0.26 (*) 2.23 ± 0.26 (*) 2.29 ± 0.57 (*) 
 
 
 
 
Cho/NAA 
(Mean ± SD) 
 
1X 0.66 ± 0.11 0.66 ± 0.11 0.66 ± 0.11 0.66 ± 0.11 
2X 0.68 ± 0.14 0.68 ± 0.13 0.67 ± 0.12 0.69 ± 0.13 
3X 0.68 ± 0.12 0.64 ± 0.14 0.65 ± 0.12 0.67 ± 0.14 
4X 0.68 ± 0.11 0.68 ± 0.11 0.68 ± 0.12 0.66 ± 0.16 
5X 0.68 ± 0.10 0.70 ± 0.07 0.65 ± 0.12 0.66 ± 0.13 
7X 0.7 ± 0.09 0.62 ± 0.10 0.65 ± 0.10 0.67 ± 0.12 
10X 0.73 ± 0.07 (*) 0.65 ± 0.12 0.66 ± 0.09 0.72 ± 0.11 (*) 
 
 
 
 
Cho/Cr 
(Mean ± SD) 
 
1X 1.62 ± 0.42 1.62 ± 0.42 1.62 ± 0.42 1.62 ± 0.42 
2X 1.56 ± 0.29 1.53 ± 0.24 1.54 ± 0.23 1.61 ± 0.39 
3X 1.47 ± 0.20 1.48 ± 0.21 1.50 ± 0.24 1.53 ± 0.35 
4X 1.46 ± 0.22 (*) 1.56 ± 0.23 1.57 ± 0.32 1.48 ± 0.30 
5X 1.53 ± 0.20 1.53 ± 0.16 1.46 ± 0.26 (*) 1.50 ± 0.21 
7X 1.43 ± 0.18 (*) 1.46 ± 0.16 (*) 1.41 ± 0.23 (*) 1.49 ± 0.19 (*) 
10X 1.60 ± 0.43 1.46 ± 0.28 (*) 1.42 ± 0.22 (*) 1.58 ± 0.40 
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Figure 5.9 The PSFs of the four types of masks at each acceleration factor. (LR – Low 
Resolution, VD – variable density) 
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As seen from Table 5.1, at 2X acceleration there are no statistically significant 
differences between the metabolite ratios from each sampling scheme and the 1X fully 
sampled reference. Significant differences in the metabolite ratios are seen between the 
1X and (3X – 5X, 7X, 10X) datasets reconstructed using the low resolution sampling 
mask. Both a priori and VD undersampling show no statistical significance (p > 0.05) up 
to 5X, while the iterative design reconstructions show fidelity up to 4X when compared 
with the 1X reference. All reconstructions from the four sampling schemes fail at 7X and 
10X.   
 
5.3.3 Discussion & Conclusions 
A preliminary study was conducted to assess the effect of different undersampling 
masks on the CS-MRSI reconstruction quality. Four sampling schemes, namely low 
resolution, VD, iterative design, and a priori were retrospectively evaluated on a 
phantom MRSI dataset. The a priori and VD undersampling masks can be considered 
equivalent to the ‘Key-thresh’ and ‘CS-points’ masks previously employed by our group 
for fast acquisitions in dynamic contrast enhanced (DCE) MRI [174], with 
reconstructions maintaining high statistical fidelity up to 5X acceleration. All 
retrospectively generated CS-MRSI datasets were reconstructed using the algorithm 
described in [71], which was previously employed in Chapters 3, 4, and 5 of this 
dissertation. Reconstruction parameters were kept the same across the board to ensure 
that any resulting differences can be attributed to the type of mask being employed. 
Simulation results indicate that both the a priori and VD undersampling masks maintain 
high fidelity with the 1X reference up to 5X acceleration. The low resolution 
reconstructions showed statistically significant differences from the 1X with increased 
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undersampling. The breakdown in reconstruction even at a relatively lower acceleration 
such as 3X can be attributed to the placement of all samples at the k-space center, which 
does not satisfy the random undersampling criterion necessary in CS.  
The iterative sampling method was quantitatively comparable to the a priori and 
VD undersampling schemes even at higher accelerations. In this experiment, no 
distinction was made between the low and high frequency locations of k-space when 
selecting the points with maximum error, contrary to that employed previously by Liu et 
al [172]. This approach was chosen to ensure a brute-force evaluation of the k-space error 
locations since the computational complexity of evaluating a low resolution 16 x 16 
spatial grid in MRSI is comparatively low as compared to the matrix sizes employed in 
MRI. In the test datasets, the iterative design approach showed a tendency towards 
sampling the center more densely as compared to the peripheral regions of k-space (as 
can be seen from the masks in Figures 5.4 – 5.6), indicating that a sampling of lower 
frequencies reduces the reconstruction error more than the higher frequencies. A similar 
result has been found in a recent study conducted by Zijlstra et al [156]. Future work 
could involve partitioning the k-space into high and low frequency regions while 
checking for the maximum error, in order to ensure an optimal ratio of low/high 
frequency sampled locations. The iterative design method is tailored to each specific 
dataset, is retrospective in application, and can be computationally expensive, particularly 
when using larger grid sizes. More extensive simulations are required to determine 
whether the same mask can be employed for a particular anatomy for e.g. in brain MRSI.  
VD undersampling suggested by Lustig et al has shown high reconstruction 
fidelity in the datasets evaluated in various published CS-MRSI studies [71, 72, 85] as 
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well as those included in this thesis. While the VD method satisfies the CS requirement 
of pseudo-random undersampling, not all masks might be good candidates to achieve an 
accurate reconstruction. Furthermore, for low resolution MRSI datasets, only assessing 
the PSF (and degree of incoherence) of a sampling pattern may not be the only major 
criterion in determining an optimal mask. An observation along these lines has previously 
been made while investigating undersampling patterns in MRI [57, 156]. Due to the 
limited number of sampling points in MRSI, a less than optimal placement of even a few 
samples might lead to an inaccurate reconstruction. 
The a priori mask was extracted from the k-space of the anatomical scout that 
was acquired using the same FOV as the MRSI data. The k-space was cropped to match 
the size of the MRSI grid (16x16) and the highest energy locations were selected to 
design a mask at the desired undersampling factor. The a priori mask is simple to 
implement as an accompanying anatomical reference is always acquired prior to the 
MRSI scan. Thus, this mask can be prospectively implemented on the scanner and offers 
the added advantage of being tailored to the acquired MRSI data.  
In conclusion, a preliminary attempt was made to identify an optimal sampling 
mask in MRSI. More extensive simulations and quantitative comparisons could help 
determine a library of masks best suited to a particular application/dataset/anatomy. Other 
factors such as optimizing the regularization coefficients and the reconstruction 
algorithm, along with identifying an optimal sampling density for each data type could 
improve reconstruction accuracy in CS-MRSI. 
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CHAPTER 6 
CONCLUSIONS & FUTURE DIRECTIONS 
 
The development of fast data acquisition strategies can contribute to the 
availability of more diagnostic information in healthcare as it could help accommodate 
more MR sequences and protocols within the current clinical examination window. On 
the other hand, rapid exam protocols could potentially offer other benefits like reduced 
costs, increased patient throughput, less patient discomfort, and lower susceptibility to 
motion artifacts. The advancement of fast imaging techniques is, thus, critical for the 
establishment of sophisticated yet affordable patient care. This dissertation primarily 
focused on accelerating magnetic resonance spectroscopic imaging (MRSI) using 
compressed sensing (CS). CS-MRSI sequences were implemented on both preclinical 
and clinical scanners and both fully-sampled and accelerated MRSI data was acquired 
(prospective) or simulated (retrospective) in phantoms, small animals (mice), human 
volunteers, and patients using three different MRI scanner platforms. Both prospectively 
and retrospectively undersampled MRSI datasets were reconstructed offline in Matlab 
using a convex optimization algorithm to obtain the best estimate of the accelerated 
MRSI data in comparison with the fully-sampled 1X reference. The reconstruction 
accuracy and spectral fidelity of all CS-MRSI datasets was further assessed by making 
quantitative comparisons between the 1X and undersampled datasets in terms of the peak 
metabolite amplitudes, relative metabolite ratios, the normalized root mean square error 
(nRMSE), and the total acquisition time. A pilot test was also conducted to identify an 
optimal sampling mask for CS-MRSI at each acceleration factor. 
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6.1   Preclinical CS-MRSI 
CS was employed to speed-up spectroscopic imaging on the Bruker 7 T small 
animal MRI scanner, as detailed in Chapter 3. The lactate-CS-MRSI sequence achieved 
rapid mapping of the lactate peak both in vitro and in vivo in mice subcutaneously 
implanted with H1975 tumor cells. In the phantom, accelerations up to 10X showed no 
statistically significant differences from the gold standard, while prospectively 
undersampled MRSI acquisitions in tumor mice demonstrated negligible information loss 
and high fidelity even when only 20% of the k-space space locations were sampled (5X 
acceleration). In all experiments, it was demonstrated that CS can accelerate MRSI by 
five-fold, with negligible reconstruction errors and having statistical equivalence (p > 
0.05) with the 1X fully sampled reference data.   
Preclinical imaging is more SNR limited as compared to clinical imaging as the 
acquisition parameters such as the field of view (FOV) and slice thickness are often an 
order of magnitude lower than those employed while imaging humans. This leads to 
smaller voxel sizes, thus, reducing the SNR particularly in hard to image areas that are 
more prone to motion or susceptibility artifacts. Higher averages are commonly required, 
especially in vivo, to achieve adequate SNR. For e.g. the acquisition of a 16 x 16 x 2048 
spectroscopic grid in the mouse MRSI datasets illustrated in Chapter 3 necessitated at 
least 4 signal averages to obtain adequate SNR, which resulted in a total scan time of 25 
min 36 s with a TR = 1500 ms at 7 T for the fully sampled 1X MRSI dataset. The 
selected FOV of 27.2 x 27.2 mm2 and slice thickness of 3 mm resulted in voxels that 
were 1.7 mm x 1.7 mm x 3 mm. On the other hand, an in vivo clinical scan of the adult 
brain would for e.g. cover a FOV 100 x 100 x 15 mm3, and for the same 16 x 16 spatial 
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grid result in voxels that are 6.25 mm x 6.25 mm x 15 mm, ~4X larger than those in small 
animals. Often a single signal average would suffice to achieve optimal SNR (6 min 24 s 
with TR = 1500 ms) for e.g. when scanning the brain, although longer scan times may be 
necessary in SNR limited organs such as the prostate. 
Such lengthy scan times are not desirable when imaging animals that are typically 
anesthetized during the experiment. Particular care also needs to be taken when 
performing repeated measurements on the same animal at different time points. 
Furthermore, it is not possible to perform dynamic imaging studies and capture the subtle 
changes for e.g. in tumor metabolism using such lengthy acquisition protocols. In view of 
the above, CS accelerated MRSI can help achieve rapid mapping of important biomarkers 
with high fidelity. The time gained from CS-MRSI can also be utilized to improve 
detection of the smaller metabolites like 2-hydroxyglutarate (2HG), glycine, alanine, and 
glutamate, which have proven to be important markers in various malignant tumors [167, 
168, 175, 176]. These harder to detect metabolites typically require increased averaging 
to achieve sufficient SNR, due to their relatively smaller amplitudes as compared to the 
standard metabolites like choline, creatine and NAA. On the other hand, the improved 
detection of smaller metabolites that are amenable to spectral editing using an accelerated 
editing sequence (e.g. the lactate-CS-MRSI sequence) may not require higher averages. 
This would thus, not offset the time gained from CS-MRSI. The lactate-CS-MRSI 
sequence can be employed to capture the changes in tumor lactate metabolism in 
response to an imaging probe or therapy, as demonstrated in Chapter 3.  
Preclinical MRI scanners facilitate non-invasive imaging at the molecular and 
cellular level, which is a critical tool in cancer pharmacology studies. Probing cellular 
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activity and dysfunction, particularly in cancer metabolism, can aid in the testing and 
development of new drugs and treatment strategies. Preclinical trials offer greater insights 
as compared to in vitro studies and can help in tumor phenotyping and longitudinal 
evaluations of disease progression and therapeutic outcomes. Fast data acquisition 
techniques have the potential to play a pivotal role in realizing the goals of preclinical 
imaging. 
 
6.2   Clinical CS-MRSI 
The clinical applications of CS-MRSI were detailed in Chapters 4 and 5. The 
retrospective application of CS to MRSI was demonstrated in 20 pediatric patients 
scanned for various brain related concerns, in Chapter 4. The undersampled 
reconstructions maintained high fidelity and statistical similarity (p > 0.05) with the 1X 
reference even at 80% undersampling, similar to that seen with the preclinical CS-MRSI 
datasets. The main limitation of this study was that it was performed retrospectively using 
the fully sampled 1X MRSI data for each patient. Future work could involve 
implementing a library of the best pseudo-random undersampling masks corresponding to 
each acceleration factor on the Philips 3 T Ingenia scanner to enable prospective CS 
acquisitions. More in vitro and in vivo clinical applications of CS-MRSI were discussed 
in Chapter 5, including phantom results from the prospective k-space undersampling 
implemented on the GE Discovery 3 T MRI scanner. Other aspects involved determining 
the best pseudo-random undersampling mask tailored to MRSI at each acceleration 
factor, identifying the acceleration factor at which the reconstruction algorithm failed, 
and optimization of the CS-MRSI reconstruction algorithm. Future work in these areas 
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would require testing more methods to determine the ‘most optimal’ mask for CS-MRSI 
depending on the application/type of dataset along with improving the cost 
function/functional of the non-linear iterative reconstruction algorithm, to better exploit 
the CS sparsity criterion. 
The primary objective of this thesis was to establish the utility of fast MRSI, in 
particular CS accelerated MRSI, in order to make a strong case for routine MRSI exams 
in the clinic. Determination of the most optimal parameters for prospective CS-MRSI and 
extensive validation of the reconstruction accuracy would give the clinician confidence to 
exclude the 1X fully sampled MRSI scan. Extension of CS-MRSI to three spatial 
dimensions would enable one to exploit the sparsity along the slice direction, leading to 
potentially higher acceleration factors and corresponding reduction in the scan time. 
However, as previously discussed in Chapter 4, acquisition of 3D fully-sampled MRSI 
datasets in patients is not possible due to the prohibitive scan time. Prospective 3D CS-
MRSI scans can, however be tested in patients if the reconstruction fidelity has been 
sufficiently validated in human volunteers.  
Furthermore, the acquisition of MRSI data involves complicated steps like B0 
shimming and water/lipid suppression, which play a critical role in determining the 
quality of MRSI data. This would require specialized operator training as in most cases a 
manual optimization of the above parameters is required to achieve the desired spectral 
quality. Another aspect to be considered is the implementation of CS reconstruction 
routines on the scanner for immediate viewing of the spectroscopic data. This is 
essentially complicated by the fact that a CS reconstruction takes ~ 4 min for a 2D MRSI 
dataset on a 3 GHz computer (for the 16 x 16 x 2048 datasets illustrated in this thesis), 
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with larger grid sizes and datasets of higher dimensionality requiring more computation 
time [72, 78, 93]. Reconstructed MRSI data also requires a series of post-processing 
operations that need to be applied before presenting the final metabolite maps/spectra for 
interpretation. Such long processing times are not practical for routine clinical use and 
would necessitate high speed computing routines that are compatible with the scanner 
software. 
The non-linear iterative CS reconstruction preserves the spectral line shapes but at 
the same time causes a gradual smoothing of the spectra with increasing acceleration. 
This is due to the denoising introduced by the wavelet and total variation terms in the 
functional of the CS reconstruction algorithm. CS denoising could lead to a smoothing of 
smaller metabolites that are close to the noise floor in the MRS spectrum, thus, presenting 
the disadvantage of missing these less prominent signals altogether. This dissertation 
focused on the larger metabolites, namely, NAA, creatine, choline, and lactate, which 
appear as prominent peaks in the MRS spectrum. However, there are other smaller 
metabolites such as alanine, glycine, glutamate, 2HG, and myo-inositol that are important 
biomarkers and relatively hard to detect. In such cases, the reconstruction algorithm 
would need to be tailored to ensure a reliable representation of low concentration 
metabolites at higher accelerations, especially when the acquired MRSI data is SNR 
limited.  
In studies involving these smaller metabolites, one could also choose to offset the 
time gained by employing increased signal averaging to boost the SNR. Future studies 
could focus on investigating the true sensitivity of metabolite detection as a function of 
scan time to optimize various parameters in the CS reconstruction algorithm. 
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Furthermore, smaller metabolites that are amenable to spectral editing can be selectively 
acquired when their detection and quantification is critical. While this approach removes 
all other metabolite peaks in the spectrum, the biomarker of interest (for e.g. lactate) can 
be reliably captured with a corresponding gain in time when combined with CS 
acceleration. This would, however, require the development and implementation of 
specialized pulse sequences tailored to the metabolite of interest.     
 
6.3   Future Directions: Multi-parametric Assessment of Cancer 
Inclusion of MRSI in scan protocols is essential for a true multi-parametric 
assessment of cancer, on both the clinical and preclinical fronts. The information from 
various MRI sequences like diffusion weighed imaging (DWI), dynamic contrast 
enhanced imaging (DCE), and MRSI would enable the clinician to assess different 
parameters and variations from voxel-to-voxel, leading to potentially improved diagnosis 
and treatment strategies. The non-invasive extraction of various quantitative parameters 
like the tumor perfusion, pO2, apparent diffusion coefficient (ADC), and metabolite 
concentrations necessitates a multi-modality approach that achieves a differential gain in 
information from different techniques that probe cancer metabolism. An optimal trade-off 
between various parameters like the resolution, SNR, sensitivity, penetration depth, 
artifacts, imaging speed, and costs will facilitate a more comprehensive multi-parametric 
assessment in cancer targeting and therapeutics.   
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APPENDIX A 
A FASTER PISTOL FOR 1H MR-BASED QUANTITATIVE TISSUE OXIMETRY 
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This section is based on the paper – “A Faster PISTOL for 1H MR-based 
quantitative tissue oximetry”, R. Vidya Shankar and V. D. Kodibagkar, in submission to 
NMR in Biomedicine. 
 
A.1   Introduction 
The normal functioning of various tissues and organs in the human body is 
dependent on the efficient delivery of oxygen. Tissue oximetry techniques are 
increasingly playing an important role in the assessment and monitoring of various 
pathologies such as in traumatic brain injury [177-179], ischemic stroke [180-186], 
wound healing [187], in cellular tracking and imaging the health of labeled cells [188-
192], resuscitation approaches in critical organ beds [193], and for monitoring oxygen 
dynamics in cancer [194-196]. Numerous factors can cause tissue to develop hypoxic 
(low oxygen tension, pO2) regions such as impaired perfusion, breakdown in diffusion 
processes, reduced oxygen transport functionality of blood in conditions like anemia, 
increased cellular cytotoxicity, and low blood oxygen tension commonly seen in 
pulmonary diseases [197, 198]. Solid tumors tend to have hypoxic foci that contribute to 
malignant progression and poor therapeutic response [199]. Histological studies have 
revealed extensive hypoxic regions in various tumors of the brain, breast, and prostate 
[200-202], with very high resistance to radiotherapy identified in severely hypoxic 
tumors [203-205]. The mapping of tissue pO2 in vivo may be critical in furthering 
investigations of the mechanisms that underlie tissue function, particularly in predicting 
therapeutic outcomes for individual patients as well as in the design of efficacious 
therapeutic combinations [206, 207]. Furthermore, fast routine tissue oxygenation 
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measurements in individual organs will enable the clinician to evaluate and prescribe 
defined endpoints for medical interventions, along with an optimized use of hyperoxic 
oxygen in various medical therapies. 
PISTOL (Proton Imaging of Siloxanes to map Tissue Oxygenation Levels) is a 
recently developed oximetry technique in proton MRI that is based on the relaxometry of 
siloxanes such as hexamethyldisiloxane (HMDSO) [208]. HMDSO has been identified as 
a promising 1H pO2 reporter molecule as its spin-lattice relaxation rate R1 tends to exhibit 
a linear dependence on the pO2, particularly in the temperature range 26 – 46 
oC [209]. 
The PISTOL sequence has been designed to selectively excite and map the T1 of the 
siloxane 1H resonance (~ 0 ppm), while simultaneously suppressing the peaks from water 
and fat. One can subsequently use PISTOL to map the tissue pO2 at various locations 
where siloxanes (neat or emulsified) have been exogenously administered or accumulated 
after endogenous administration. This sequence can also be used to record the dynamic 
changes in the tissue pO2 in response to intervention [208, 210] or for imaging and 
oximetry of siloxane labelled cells [190, 191].  
The PISTOL sequence requires 3 minutes 45 seconds to map the T1, and hence 
pO2, of exogenously administered HMDSO at 7 T. A faster oximetry sequence could be 
particularly useful in studies where dynamic changes in the tissue pO2 need to be rapidly 
recorded in response to gas intervention. Hence the primary objective of this study was to 
develop a faster siloxane-selective relaxometry sequence and to compare it, in vitro and 
in vivo, with the PISTOL sequence using metrics such as the total imaging time and 
fidelity of the acquired relaxometry data. 
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A.2   Materials and Methods 
PISTOL-LL Pulse Sequence for pO2 measurement  
A new oximetry sequence, henceforth referred to as PISTOL-LL (Figure A.1), 
was developed by modifying the PISTOL pulse sequence [208] where the ARDVARC 
magnetization preparation scheme was replaced by a frequency-selective version of the 
Look-Locker [211, 212] approach. The PISTOL-LL sequence, depicted in Figure A.1, 
consists of a frequency-selective π inversion recovery preparation pulse, followed by a 
sequence of 55 low flip-angle αo pulses, with a delay τ between two successive pulses. 
The small flip angle α pulses are also frequency selective for the HMDSO resonance. 
Each α pulse is immediately followed by an EPI readout/module, thus, enabling multiple 
(in this case 55) image acquisitions within the same TR. An excitation angle of α = 5o 
was employed. The magnetization recovery curve was sampled linearly using 55 equally 
spaced αo pulses, with the spacing between two subsequent αo pulses being τ = 1000 ms 
(TR = 55 s). Thus, the PISTOL-LL sequence enabled T1 mapping of HMDSO in ~55s. 
For the PISTOL acquisitions, the T1 measurements were obtained using the 
ARDVARC (alternating relaxation delays with variable acquisitions for reduction of 
clearance effects) protocol, as employed previously [208]. The total scan time for each T1 
map acquired using PISTOL was 3 minutes 45 seconds. PISTOL and PISTOL-LL were 
implemented on a horizontal-bore Bruker BioSpec® 7 T preclinical MRI scanner with 
actively shielded gradients and all in vitro and in vivo experiments were conducted on 
this scanner. An HMDSO-selective chemical-shift selective spin-echo sequence was 
initially used to locate the HMDSO resonance. Both PISTOL and PISTOL-LL were 
subsequently run to measure the T1 of HMDSO at the chosen slice location. 
146 
 
 
Figure A.1 Pulse sequence diagram for HMDSO-selective oximetry using PISTOL-LL. 
The sequence consists of a frequency-selective π inversion recovery preparation pulse, 
followed by N = 55 α = 5o pulses (also HMDSO selective), with a delay τ = 1s between 
two successive αo pulses. An EPI readout follows each αo pulse, enabling a linear 
sampling of the magnetization recovery curve within the same TR (55 s). 
 
Both the PISTOL and PISTOL-LL datasets were processed offline using home-
built algorithms in Matlab to compute T1, R1 (=1/T1), and pO2 maps using calibration 
curves corresponding to PISTOL and PISTOL-LL at 7 T, respectively (Figure A.2 (a)) on 
a voxel-by-voxel basis. For the PISTOL measurements, the T1 values were computed for 
each voxel by appling a three-parameter least-squares curve fit to the measured signal 
intensities from 16 τ values using the Levenberg-Marquardt algorithm.  
For the PISTOL-LL measurements, the curve-fitting procedure corresponding to 
inversion recovery was applied to the measured signal intensities from 55 τ values, for 
each voxel. A three parameter fit was applied to the recovery curve 1
 = @ −
ABC− #	∗⁄ 
 to obtain A, B, and T1*. It is difficult to directly obtain T1  from T1*  as the 
RF coil profile and B1 field inhomogeneities lead to imperfections in the flip angle α at 
each pixel location, causing it to differ within the sample [213, 214]. When α is small (5o 
in our experiments), #	 =  #	∗A @F − 1
 can be employed to correct for the longitudinal 
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relaxation time [214]. Lastly, the R1 maps from both sequences were then converted into 
pO2 maps using the calibration curves for HMDSO at 7 T.   
 
In Vitro Calibration and Phantom Experiments 
For the calibration experiments, a second phantom consisting of four gas-tight 
John Young NMR tubes (Wilmad Labglass, Buena, NJ, USA) was constructed. Each of 
these four tubes housed 1 ml of HMDSO bubbled with different concentrations of oxygen 
(0%, 5%, 10%, and 21% calibrated gases). The phantom was placed on a warm heating 
pad connected to a circulating water bath and the temperature was monitored using a 
fiber-optic temperature probe (FISO Technologies Inc., Quebec City, Quebec, Canada). 
Both the PISTOL and PISTOL-LL sequences were run to obtain the calibration constants 
for HMDSO at 7 T. Mean T1 values were measured from the region of interest 
corresponding to each tube. Mean R1 values were obtained from repeated measurements 
and plotted versus pO2 to generate the calibration curve for HMDSO. 
A test phantom was constructed to evaluate and optimize the PISTOL-LL 
oximetry sequence. The phantom consisted of three tubes containing HMDSO, mineral 
oil (to represent fat), and water. A 5 mm NMR tube containing HMDSO was placed 
inside a 15 mm tube containing mineral oil, and this setup was in turn placed inside a 
larger 50 ml tube housing deionized (DI) water; all three tubes were tightly sealed to 
ensure no leakage. Both the PISTOL and PISTOL-LL oximetry sequences were tested on 
the phantom to compare the ability to selectively excite the HMDSO resonance, while 
suppressing the peaks from water and fat. R1 maps were generated from the T1 maps that 
were obtained by fitting the data on a pixel-by-pixel basis as described previously. The 
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mean T1 (and R1) values over the region of interest were obtained and the pO2 values 
over the selected region were subsequently calculated using the calibration constants 
obtained as described above. 
 
In Vivo Experiments  
Approval was obtained from the Institutional Animal Care and Use committee of 
Arizona State University for all in vivo experiments. A cohort of six (n = 6) healthy 
Fischer F344 rats was used for the pO2 experiments. The rats were anesthesized via 
isoflurane gas inhalation (air and 2% isoflurane) and remained passively restrained 
during the imaging experiment. 30-50 µL of HMDSO was injected along two to three 
directions in the same plane into the left thigh muscle of each rat for the in vivo pO2 
measurements. A 72 mm volume transmit coil combined with a surface receive coil was 
employed for the in vivo studies. The rats were placed in a prone position inside the 
magnet and the left thigh muscle along with the hind leg was carefully positioned under 
the surface coil. The rats were kept warm by placing them on a heating pad connected to 
a circulating water bath operating at 37o C.  
A siloxane-selective echo planar imaging (EPI) sequence was initially used to 
locate the reporter molecule and a cross section through the thigh at the desired slice 
location was subsequently imaged. The rats were subjected to respiratory challenge by 
supplying air (~20 min) – oxygen (~30 min) – air (~30 min), as employed previously 
[208], to introduce modulation in the tissue oxygenation. A set of T1 datasets was 
collected every 5 min by running both the PISTOL (3 min 45 s) and PISTOL-LL imaging 
(55 s) sequences in an interleaved manner. The datasets were processed offline using in 
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house Matlab fitting routines to generate pO2 maps from the R1 values. Sixteen pO2 maps 
were obtained for each of the PISTOL and PISTOL-LL oximetry sequences over a time 
interval of ~80 minutes. 
 
A.3   Results 
Phantom Experiments 
Figures A.2 and A.3 illustrate the results from the phantom experiments. The 
PISTOL-LL sequence was able to successfully eliminate the signals from water and 
mineral oil as well as the siloxane-selective spin-echo and PISTOL sequences. A linear 
fit to the pO2 calibration phantom data from the PISTOL sequence generated a calibration 
curve R1 = (0.125 ± 0.001) + (0.109 ± 0.002)X10
-2 x pO2 while that from the PISTOL-LL 
sequence generated a calibration curve R1 = (0.124 ± 0.002) + (0.113 ± 0.004) X10
-2  x 
pO2 at 37 
oC at 7 T, as illustrated in Figure A.2 (a).  
As seen from the figure, both sequences generate similar calibration constants for 
neat HMDSO at 7 T. In Figures A.2 (c), A.2 (d), and A.2 (e), the SNR of HMDSO was 
356.96 (siloxane-selective spin echo sequence), 1600 (PISTOL at TR = 55 s), and 88.59 
(PISTOL-LL at TR = 55 s), respectively. The CNR for the frequency selective images in 
Figures A.2 (c), A.2 (d), and A.2 (e) with respect to water was calculated to be 343.29, 
1597.4, and 85.16, respectively, while that with respect to fat was determined to be 
337.17, 1573.7, and 83.78, respectively. 
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Figure A.2 Comparison of calibration curves and siloxane selectivity between PISTOL 
and PISTOL-LL. (a) The calibration curve obtained from a linear fit of the PISTOL data 
is given by R1 = (0.125 ± 0.001) + (0.00109 ± 0.00002) x pO2, while that from the 
PISTOL-LL sequence is given by R1 = (0.124 ± 0.002) + (0.00113 ± 0.00004) x pO2 at 
37 oC and 7 T. (b) Phantom consisting of sealed tubes of water/oil/HMDSO. HMDSO 
images from the (c) frequency-selective spin-echo sequence, (d) PISTOL (TR=55s), and 
(e) PISTOL-LL (TR=55s) show complete fat and water suppression.  
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Figure A.3 PISTOL and PISTOL-LL sequences run on the water/oil/HMDSO phantom: 
T1 maps in (a) and (e), and T1 error maps in (b) and (f) for the PISTOL and PISTOL-LL 
sequences, respectively. Figures (c) and (g) depict the corresponding pO2 maps and the 
pO2 error maps for (d) PISTOL and (h) PISTOL-LL, respectively. The magnetization 
recovery curves from the two sequences are depicted in (i) and (j) for PISTOL 
(saturation-recovery) and PISTOL-LL (inversion recovery), respectively. 
 
PISTOL and PISTOL-LL sequences were both run on the water/mineral 
oil/HMDSO phantom described earlier to map the T1 of HMDSO and the results obtained 
at 7 T are as illustrated in Figure A.3. The mean T1 of HMDSO in air i.e. 21% oxygen 
concentration at 7 T determined from the PISTOL sequence is 3.47 ± 0.12 s, while that 
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from the PISTOL-LL sequence is 3.61 ± 0.29 s. The mean T1 error from the PISTOL fit 
routine is 0.41 ± 0.05 s, while that from PISTOL-LL is 0.46 ± 0.13 s. The mean pO2 as 
determined from the PISTOL sequence is 150.6 ± 8.8 torr, while that from the PISTOL-
LL sequence is 145.6 ± 22.7 torr. The resulting pO2 error from the PISTOL fit was found 
to be 31.43 ± 2.62 torr, while that from the PISTOL-LL sequence was 30.09 ± 2.62 torr. 
 
In Vivo Studies 
HMDSO was readily detected by both the PISTOL and PISTOL-LL sequences, 
along with complete fat and water suppression in vivo, as seen in Figure A.4. Frequency-
selective spin-echo and EPI sequences were initially employed to identify the distribution 
of the HMDSO reporter molecule, as seen in Figure A.4 (b). In Figures A.4 (b), A.4 (c), 
and A.4 (d), the SNR of HMDSO was 541.31 (siloxane-selective spin echo sequence), 
407.98 (PISTOL at TR = 55 s), and 23.37 (PISTOL-LL at TR = 55 s), respectively. The 
T1 and pO2 maps generated from the data acquired by the PISTOL and PISTOL-LL 
sequences show the same distribution of HMDSO, as illustrated in Figure A.5. The effect 
of breathing oxygen on the changes in the muscle pO2 was evaluated during the in vivo 
experiments for both the sequences under consideration. In the rat thigh muscle (n = 6), 
the baseline pO2 value for the imaging data recorded using the PISTOL sequence ranged 
from 41 to 78 torr (mean 58 ± 10 torr), while the baseline pO2 value for the data acquired 
by the PISTOL-LL sequence ranged from 40 to 76 torr (mean 59 ± 9 torr) within the 
pooled cohort.  
A significant increase (p < 0.05, compared to baseline) in the pO2 values was 
recorded by the first measurement (5 min) after the gas inhaled by the rats was switched 
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to 100% oxygen breathing; the pO2 values continued to rise over a 30 minute time 
interval during which pure oxygen was supplied. At the end of 30 minutes of oxygen 
breathing, the pO2 values ranged from 112 to 284 torr (mean 192 ± 66 torr) as recorded 
by the PISTOL sequence, while those for the PISTOL-LL sequence ranged from 86 to 
277 torr (mean 184 ± 67 torr). When the inhaled gas was switched back to air, a rapid 
drop in the pO2 values was observed (as expected), with the detected values settling down 
to near baseline measurements after approximately 30 minutes of switching back to air 
breathing. At the end of the last 30 minute interval, the pO2 values recorded by the 
PISTOL sequence ranged from 63 to 82 torr (mean 74 ± 8 torr), while the pO2 
measurements mapped by the PISTOL-LL sequence ranged from 70 to 86 torr (mean 76 
± 6 torr). Figure A.6 shows the mean pO2 values mapped from the PISTOL and PISTOL-
LL sequences for the entire time course of air – oxygen - air breathing over a time 
interval of ~80 minutes. 
 
 
Figure A.4 HMDSO-selective oximetry in vivo (a) T2-weighted image of a representative 
rat thigh muscle, (b) Frequency-selective spin-echo image of the HMDSO injected into 
the thigh muscle, (c) PISTOL image at TR = 55s, and (d) PISTOL-LL image at TR = 
55s. 
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Figure A.5 T1 and pO2 maps from PISTOL and PISTOL-LL. Time course PISTOL (a, b, 
c) and PISTOL-LL (d, e, f) T1 maps, respectively, in response to gas intervention: 
baseline air breathing (a, d), after 30 mins of oxygen breathing (b, e), and 30 mins after 
returning to breathing air (c, f). Corresponding time course PISTOL (g, h, i) and 
PISTOL-LL (j, k, l) pO2 maps, respectively, in response to gas intervention: baseline air 
breathing (g, j), after 30 mins of oxygen breathing (h, k), 30 mins after returning back to 
breathing air (i. l). 
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Figure A.6 Dynamic changes in the rat thigh muscle pO2 values in response to gas 
intervention – (a) From PISTOL, and (b) From the PISTOL-LL sequence. The three time 
points depicted correspond to the start of air breathing, 30 mins after switching to oxygen 
breathing, and 30 mins after switching back to air. (c) Mean pO2 values for all the rats 
(n=6) over the time course air-O2-air. The two methods give similar results (p > 0.05) 
when compared under air and oxygen. (d) Mean pO2 values for all the rats (n=6) over the 
entire 80 min time course air (20 min) - O2 (30 mins) – air (20 mins). (* = p < 0.05 
between PISTOL and PISTOL-LL measurements). 
 
A.4   Discussion & Conclusions 
PISTOL-LL, enables T1 and subsequently pO2 mapping of the HMDSO 
1H 
resonance in under one minute at 7 T. This results in the speeding-up of 1H MR tissue 
oximetry by ~4X compared to PISTOL. The new oximetry technique could be 
particularly useful as the T1 of HMDSO ranges from ~2.5 s (160 torr, hyperoxic 
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conditions) to ~11 s (0 torr, anoxic conditions). This results in relatively long scan times 
in MR oximetry as the minimum TR for the pulse sequence has to be chosen to equal at 
least five times the T1 of the reporter molecule under investigation. PISTOL-LL will also 
further accelerate the mapping of tissue pO2 changes when using siloxanes with T1 
recovery times that are shorter than HMDSO. 
The results demonstrate that both the PISTOL and PISTOL-LL sequences give 
statistically similar (p > 0.05) results during baseline air breathing and at the end of the 
30 minute interval after switching the inhaled gas back to air. The mean pO2 values 
recorded by both these sequences were slightly different in the 30 minute time interval 
when the rats were subjected to 100% oxygen breathing. This difference in mean pO2 
values is expected as both sequences were run in an interleaved manner and the dynamic 
changes in the muscle pO2 at any particular instant cannot be captured by both sequences 
simultaneously. However, it is fair to expect comparable mean pO2 values from the two 
sequences at the beginning (during 20 minutes of baseline air breathing) and end (30 
minutes after return to air breathing) of the experiment. This is indeed the case as 
discussed before and is illustrated in Figures A.6 (a) – A.6 (d). 
There are minor differences in the T1 values measured by the two sequences 
under consideration also due to the fact that the data is acquired using two separate 
sequences that employ two different recovery mechanisms - PISTOL is essentially a 
saturation recovery T1 mapping sequence while PISTOL-LL samples the inversion 
recovery curve using small flip angle pulses to achieve T1 mapping. The datasets 
acquired by the two sequences differ in SNR with the PISTOL-LL sequence having 
lower SNR due to the low tip angle excitation pulses (α = 90o for PISTOL and a series of 
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α = 5o pulses for PISTOL-LL). The PISTOL-LL selective images at TR = 55s (Figures 
A.2 (e) and A.4 (d)) have a SNR that is ~18x lower than that of the corresponding 
PISTOL images (Figures A.2 (d) and A.4 (c)). Different fit routines employed to post 
process the datasets from the two sequences also contribute to minor differences in the 
reported T1, R1, and pO2 values. However, the T1 values from both fit routines are very 
similar, with only minor differences even in the curve fit errors, as noted previously in 
the results. This suggests that the PISTOL-LL sequence achieves accurate T1 (and pO2) 
mapping that is comparable to the PISTOL sequence, in spite of having an ~18x lower 
SNR. 
It has been demonstrated that the new oximetry sequence PISTOL-LL has an 
improved performance with the PISTOL sequence; PISTOL-LL preserves the fidelity of 
the acquired relaxometry data, while accelerating data acquisition by ~4X. PISTOL-LL 
could be employed to image other siloxanes [215] that offer superior performance and 
have shorter T1 relaxation times as compared to HMDSO, thus, resulting in even faster 
acquisition times in MR oximetry. This sequence also has applications for in vivo tumor 
hypoxia imaging using nitromidazole-based T1 contrast agents like GdDO3NI [216, 217] 
to aid in validation. This technique could potentially be translated to the clinic, given the 
availability of state-of-the-art MR hardware and excellent fat and water suppression 
routines in clinical scanners. 
Furthermore, PISTOL-LL can also be adopted in 19F tissue oximetry [195, 196, 
218-222] with minor modifications. Perfluorocarbons (PFCs) have been employed in 19F 
NMR to quantitate the pO2, using the reporter molecule hexaflurobenzene (HFB) [195, 
218, 223, 224], wherein the R1 of these PFC nano emulsions exhibits a linear dependence 
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on the pO2. Cell labeling and tracking in the past few years has also been successfully 
achieved using PFC nano emulsions [192, 225-228]. PISTOL-LL can thus facilitate fast 
and dynamic pO2 mapping in various tracking and cellular labeling applications, such as 
those in neural stem cells, in both 19F and 1H oximetry studies involving dual-modality 
MRI-fluorescence probes [190, 191, 229]. Given the speed of acquisition, the PISTOL-
LL sequence can be easily incorporated into existing clinical protocols, thus, providing a 
valuable tool for fast quantitative oximetry. 
In summary, a fast MRI pulse sequence based on the Look-Locker approach was 
presented for accelerating the acquisition of T1 datasets in 
1H MR tissue oximetry. The 
new oximetry sequence, PISTOL-LL, enables rapid T1 and pO2 mapping of the HMDSO 
reporter molecule in less than one minute, resulting in a four-fold acceleration as 
compared to PISTOL. The PISTOL-LL technique can serve as a faster tool for probing 
oxygen dynamics in tissue oximetry studies.     
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APPENDIX B 
TABLES FROM CHAPTER 4
 This section includes tables containing patient demographic information and MRI/MRSI parameters for the 20 pediatric brain 
MRSI cases discussed in Chapter 4. 
Table B.1 Patient demographics and related information from MRI and MRSI for 14 non-tumor pediatric cases, scanned for other 
brain related concerns. (WM - white matter, NAA – N-acetyl aspartate, Cr – creatine, Cho – choline, Lac – lactate)  
 
Case Gender 
 
Age 
(years) 
 
Reason for MRI NAA/Cr 
(Mean ± SD) 
Cho/NAA 
(Mean ± SD) 
Cho/Cr 
(Mean ± SD) 
 
 
 
1 
 
 
 
M 
 
 
 
 
5 
 
optic atrophy, 
hypoplasia of anterior 
corpus callosum and 
optic nerves 
 
1X: 1.85 ± 1.30 
2X: 1.88 ± 1.78 
3X: 1.84 ± 1.17 
4X: 1.90 ± 1.23 
5X: 1.95 ± 1.42 
 
 
1X: 0.40 ± 0.34 
2X: 0.40 ± 0.35 
3X: 0.44 ± 0.54 
4X: 0.40 ± 0.35 
5X: 0.36 ± 0.15 
 
 
1X: 0.55 ± 0.14 
2X: 0.55 ± 0.15 
3X: 0.54 ± 0.15 
4X: 0.55 ± 0.15 
5X: 0.59 ± 0.14 
 
 
 
 
2 
 
 
 
M 
 
 
 
 
 
1 
 
 
 
seizures 
 
 
1X: 2.44 ± 1.74 
2X: 2.45 ± 1.85 
3X: 2.56 ± 2.36 
4X: 2.46 ± 1.83 
5X: 2.60 ± 2.20 
 
 
1X: 0.55 ± 0.42 
2X: 0.54 ± 0.46 
3X: 0.57 ± 0.54 
4X: 0.59 ± 0.59 
5X: 0.57 ± 0.52 
 
 
1X: 0.91 ± 0.24 
2X: 0.87 ± 0.20 
3X: 0.89 ± 0.22 
4X: 0.91 ± 0.27 
5X: 0.98 ± 0.26 
 
 
 
 
3 
 
 
 
F 
 
 
 
 
 
16 
 
 
 
concussion 
 
 
1X: 1.80 ± 1.43 
2X: 1.91 ± 1.90 
3X: 1.80 ± 1.39 
4X: 2.00 ± 1.84 
5X: 1.71 ± 1.10 
 
 
1X: 0.61 ± 0.41 
2X: 0.62 ± 0.40 
3X: 0.60 ± 0.39 
4X: 0.64 ± 0.40 
5X: 0.61 ± 0.37 
 
 
1X: 0.72 ± 0.15 
2X: 0.76 ± 0.24 
3X: 0.76 ± 0.23 
4X: 0.81 ± 0.30 
5X: 0.77 ± 0.24 
 
1
6
0
 
 Case Gender 
 
Age 
(years) 
 
Reason for MRI NAA/Cr 
(Mean ± SD) 
Cho/NAA 
(Mean ± SD) 
Cho/Cr 
(Mean ± SD) 
 
 
 
4 
 
 
 
M 
 
 
 
 
4 
 
 
Rathke's cleft cyst or 
pituitary 
macroadenoma 
 
 
1X: 2.25 ± 2.00 
2X: 2.48 ± 2.31 
3X: 2.62 ± 2.87 
4X: 2.55 ± 2.50 
5X: 2.45 ± 2.13 
 
 
1X: 0.40 ± 0.19 
2X: 0.36 ± 0.14 
3X: 0.35 ± 0.14 
4X: 0.35 ± 0.14 
5X: 0.34 ± 0.15 
 
 
1X: 0.67 ± 0.19 
2X: 0.67 ± 0.22 
3X: 0.65 ± 0.16 
4X: 0.65 ± 0.17 
5X: 0.65 ± 0.16 
 
 
 
 
5 
 
 
 
F 
 
 
 
 
3 
 
 
neurofibromatosis 
type 1 
and lesion in optic 
pathway/chiasm 
 
1X: 2.79 ± 1.19 
2X: 2.84 ± 1.19 
3X: 2.82 ± 1.16 
4X: 2.81 ± 1.13 
5X: 2.80 ± 1.07 
 
1X: 0.55 ± 0.69 
2X: 0.53 ± 0.62 
3X: 0.47 ± 0.32 
4X: 0.46 ± 0.33 
5X: 0.63 ± 0.47 
 
1X: 1.10 ± 0.39 
2X: 1.12 ± 0.44 
3X: 1.12 ± 0.48 
4X: 1.10 ± 0.41 
5X: 1.12 ± 0.42 
 
 
 
 
6 
 
 
 
F 
 
 
 
 
9 
 
 
seizures, temporal 
arachnoid cyst 
 
1X: 2.40 ± 1.17 
2X: 2.47 ± 1.47 
3X: 2.44 ± 1.36 
4X: 2.60 ± 1.76 
5X: 2.83 ± 2.26 
 
 
1X: 0.47 ± 0.18 
2X: 0.46 ± 0.19 
3X: 0.47 ± 0.20 
4X: 0.45 ± 0.19 
5X: 0.43 ± 0.19 
 
 
1X: 1.00 ± 0.25 
2X: 0.95 ± 0.25 
3X: 0.96 ± 0.25 
4X: 0.93 ± 0.20 
5X: 0.92 ± 0.20 
 
 
 
 
7 
 
 
 
F 
 
 
 
 
 
10 
 
 
 
encephalopathy 
 
1X: 2.49 ± 1.33 
2X: 2.70 ± 1.70 
3X: 2.69 ± 1.46 
4X: 2.70 ± 1.62 
5X: 2.65 ± 1.35 
 
1X: 0.44 ± 0.46 
2X: 0.38 ± 0.19 
3X: 0.37 ± 0.14 
4X: 0.37 ± 0.14 
5X: 0.38 ± 0.14 
 
1X: 0.87 ± 0.33 
2X: 0.84 ± 0.25 
3X: 0.84 ± 0.20 
4X: 0.85 ± 0.20 
5X: 0.83 ± 0.20 
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 Case Gender 
 
Age 
(years) 
 
Reason for MRI NAA/Cr 
(Mean ± SD) 
Cho/NAA 
(Mean ± SD) 
Cho/Cr 
(Mean ± SD) 
 
 
 
8 
 
 
 
M 
 
 
 
 
 
4 
 
 
neurofibromatosis 
type 1 - von 
Recklinghausen's 
disease 
 
1X: 2.58 ± 1.91 
2X: 2.82 ± 2.40 
3X: 2.95 ± 2.73 
4X: 2.87 ± 2.30 
5X: 2.83 ± 2.37 
 
 
1X: 0.34 ± 0.17 
2X: 0.33 ± 0.18 
3X: 0.35 ± 0.17 
4X: 0.40 ± 0.16 
5X: 0.38 ± 0.19 
 
 
1X: 0.66 ± 0.11 
2X: 0.66 ± 0.13 
3X: 0.63 ± 0.14 
4X: 0.60 ± 0.11 
5X: 0.55 ± 0.12 
 
 
 
 
9 
 
 
 
F 
 
 
 
 
 
3 
 
 
incomplete whitel 
matter myelination in 
subcortical areas 
 
1X: 1.90 ± 0.65 
2X: 1.89 ± 0.64 
3X: 1.89 ± 0.63 
4X: 1.91 ± 0.64 
5X: 1.89 ± 0.61 
 
 
1X: 0.49 ± 0.14 
2X: 0.48 ± 0.15 
3X: 0.47 ± 0.15 
4X: 0.47 ± 0.14 
5X: 0.47 ± 0.15 
 
 
1X: 0.85 ± 0.16 
2X: 0.83 ± 0.16 
3X: 0.82 ± 0.15 
4X: 0.83 ± 0.13 
5X: 0.82 ± 0.12 
 
 
 
 
10 
 
 
 
F 
 
 
 
 
 
1.1 
 
 
 
Moyamoya disease 
 
 
1X: 1.57 ± 0.33 
2X: 1.61 ± 0.35 
3X: 1.63 ± 0.32 
4X: 1.63 ± 0.32 
5X: 1.66 ± 0.34 
 
 
1X: 0.62 ± 0.15 
2X: 0.62 ± 0.14 
3X: 0.61 ± 0.12 
4X: 0.60 ± 0.11 
5X: 0.56 ± 0.09 
 
 
1X: 0.93 ± 0.13 
2X: 0.95 ± 0.13 
3X: 0.96 ± 0.13 
4X: 0.86 ± 0.14 
5X: 0.90 ± 0.12 
 
 
 
 
11 
 
 
 
F 
 
 
 
 
 
7 
 
 
 
Rathke's cleft cyst 
near the pituitaries 
 
1X: 3.06 ± 2.66 
2X: 3.12 ± 3.08 
3X: 3.17 ± 2.59 
4X: 3.42 ± 3.04 
5X: 3.42 ± 3.35 
 
 
1X: 0.41 ± 0.39 
2X: 0.39 ± 0.38 
3X: 0.40 ± 0.41 
4X: 0.38 ± 0.26 
5X: 0.37 ± 0.26 
 
 
1X: 0.89 ± 0.16 
2X: 0.88 ± 0.21 
3X: 0.88 ± 0.22 
4X: 0.85 ± 0.19 
5X: 0.78 ± 0.20 
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 Case Gender 
 
Age 
(years) 
 
Reason for MRI NAA/Cr 
(Mean ± SD) 
Cho/NAA 
(Mean ± SD) 
Cho/Cr 
(Mean ± SD) 
 
 
 
12 
 
 
 
M 
 
 
 
 
 
0.5 
 
 
 
Tuberous sclerosis 
 
 
1X: 2.07 ± 1.04 
2X: 2.20 ± 1.38 
3X: 2.34 ± 1.77 
4X: 2.45 ± 2.21 
5X: 2.45 ± 2.16 
 
 
1X: 0.89 ± 1.19 
2X: 0.80 ± 0.82 
3X: 0.71 ± 0.41 
4X: 0.72 ± 0.52 
5X: 0.71 ± 0.41 
 
 
1X: 1.24 ± 0.17 
2X: 1.27 ± 0.21 
3X: 1.28 ± 0.22 
4X: 1.28 ± 0.23 
5X: 1.29 ± 0.24 
 
 
 
 
13 
 
 
 
M 
 
 
 
 
 
2.5 
 
 
decreased WM 
volume, 
demyelination 
 
1X: 1.33 ± 0.42 
2X: 1.33 ± 0.40 
3X: 1.31 ± 0.39 
4X: 1.31 ± 0.37 
5X: 1.31 ± 0.36 
 
 
1X: 0.69 ± 0.22 
2X: 0.69 ± 0.23 
3X: 0.70 ± 0.24 
4X: 0.69 ± 0.22 
5X: 0.70 ± 0.22 
 
 
1X: 0.84 ± 0.12 
2X: 0.85 ± 0.13 
3X: 0.84 ± 0.12 
4X: 0.84 ± 0.11 
5X: 0.84 ± 0.13 
 
 
 
 
14 
 
 
 
M 
 
 
 
 
 
3 day 
 
 
posterior parietal 
cephalohematoma 
 
1X: 1.54 ± 1.80 
2X: 1.45 ± 2.21 
3X: 1.32 ± 1.51 
4X: 1.26 ± 1.12 
5X: 1.36 ± 1.47 
 
 
1X: 2.01 ± 2.62 
2X: 2.25 ± 3.15 
3X: 2.28 ± 3.47 
4X: 2.26 ± 3.48 
5X: 2.28 ± 3.13 
 
 
1X: 1.55 ± 0.63 
2X: 1.67 ± 1.09 
3X: 1.66 ± 0.91 
4X: 1.65 ± 0.90 
5X: 1.58 ± 0.72 
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 Table B.2 Patient demographics and related information from MRI and MRSI for 6 pediatric cases with brain tumors (includes 
resected cases). (NAA – N-acetyl aspartate, Cr – creatine, Cho – choline, Lac – lactate) 
 
Case Gender 
 
Age 
(years) 
 
Reason for MRI NAA/Cr 
(Mean ± SD) 
Cho/NAA 
(Mean ± SD) 
Cho/Cr 
(Mean ± SD) 
 
 
 
1 
 
 
 
M 
 
 
 
 
10 
 
 
 
Ewing’s sarcoma 
 
1X: 1.73 ± 0.55 
1.48 ± 0.41 (Tumor) 
3.37 ± 2.87 (Lac/Cr) 
2X: 1.73 ± 0.6 
1.53 ± 0.51 (Tumor) 
3.48 ± 3.21 (Lac/Cr) 
3X: 1.71 ± 0.52 
1.62 ± 0.45 (Tumor) 
4.05 ± 3.38 (Lac/Cr) 
4X: 1.7 ± 0.51 
1.62 ± 0.44 (Tumor) 
4.09 ± 4.08 (Lac/Cr) 
5X: 1.71 ± 0.48 
1.45 ± 0.25 (Tumor) 
2.87 ± 2.25 (Lac/Cr) 
 
 
1X: 0.60 ± 0.58 
0.77 ± 0.39 (Tumor) 
2.31 ± 1.95 (Lac/NAA) 
2X: 0.60 ± 0.38 
0.79 ± 0.40 (Tumor) 
2.23 ± 1.88 (Lac/NAA) 
3X: 0.58 ± 0.46 
0.81 ± 0.31 (Tumor) 
2.23 ± 2.00 (Lac/NAA) 
4X: 0.57 ± 0.38 
0.81 ± 0.30 (Tumor) 
2.23 ± 2.03 (Lac/NAA) 
5X: 0.53 ± 0.26 
0.83 ± 0.33 (Tumor) 
2.11 ± 1.68 (Lac/NAA) 
 
 
1X: 0.82 ± 0.25 
1.06 ± 0.36 (Tumor) 
3.00 ± 2.49 (Lac/Cho) 
2X: 0.84 ± 0.30 
1.12 ± 0.43 (Tumor) 
2.88 ± 2.68 (Lac/Cho) 
3X: 0.90 ± 0.48 
1.37 ± 0.86 (Tumor) 
2.72 ± 2.30 (Lac/Cho) 
4X: 0.89 ± 0.49 
1.38 ± 0.88 (Tumor) 
2.36 ± 1.40 (Lac/Cho) 
5X: 0.85 ± 0.32 
1.19 ± 0.49 (Tumor) 
2.17 ± 1.12 (Lac/Cho) 
 
 
 
2 
 
 
 
M 
 
 
 
 
 
13 
 
 
 
meningioma 
 
1X: 2.73 ± 2.44 
2X: 2.29 ± 2.48 
3X: 3.22 ± 3.13 
4X: 3.17 ± 3.90 
5X: 3.28 ± 3.95 
 
 
1X: 0.71 ± 0.79 
2X: 0.68 ± 0.80 
3X: 0.62 ± 0.60 
4X: 0.57 ± 0.34 
5X: 0.53 ± 0.35 
 
 
1X: 1.08 ± 0.35 
2X: 1.12 ± 0.49 
3X: 1.10 ± 0.35 
4X: 1.10 ± 0.38 
5X: 1.20 ± 0.40 
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 Case Gender 
 
Age 
(years) 
 
Reason for MRI NAA/Cr 
(Mean ± SD) 
Cho/NAA 
(Mean ± SD) 
Cho/Cr 
(Mean ± SD) 
 
 
 
3 
 
 
 
M 
 
 
 
 
1.5 
 
 
 
hemophagocytic 
lymphohistiocyto
sis 
 
1X: 1.72 ± 0.47 
1.42 ± 0.45 (Tumor) 
0.80 ± 0.36 (Lac/Cr) 
2X: 1.72 ± 0.48 
1.41 ± 0.43 (Tumor) 
0.76 ± 0.32 (Lac/Cr) 
3X: 1.81 ± 0.52 
1.40 ± 0.38 (Tumor) 
0.78 ± 0.22 (Lac/Cr) 
4X: 1.83 ± 0.51 
1.39 ± 0.40 (Tumor) 
0.75 ± 0.19 (Lac/Cr) 
5X: 1.82 ± 0.52 
1.38 ± 0.40 (Tumor) 
0.73 ± 0.29 (Lac/Cr) 
 
 
1X: 0.64 ± 0.30 
1.20 ± 0.50 (Tumor) 
0.63 ± 0.42 (Lac/NAA) 
2X: 0.66 ± 0.32 
1.23 ± 0.47 (Tumor) 
0.59 ± 0.32 (Lac/NAA) 
3X: 0.63 ± 0.32 
1.25 ± 0.47 (Tumor) 
0.60 ± 0.24 (Lac/NAA) 
4X: 0.61 ± 0.31 
1.24 ± 0.44 (Tumor) 
0.59 ± 0.25 (Lac/NAA) 
5X: 0.63 ± 0.32 
1.23 ±  0.44 (Tumor) 
0.53 ± 0.24 (Lac/NAA) 
 
1X: 1.02 ± 0.32 
1.60 ± 0.47 (Tumor) 
0.49 ± 0.14 (Lac/Cho) 
2X: 1.03 ± 0.31 
1.61 ± 0.45 (Tumor) 
0.46 ± 0.10 (Lac/Cho) 
3X: 1.03 ± 0.29 
1.61 ± 0.30 (Tumor) 
0.49 ± 0.11 (Lac/Cho) 
4X: 1.02 ± 0.29 
1.58 ± 0.30 (Tumor) 
0.47 ± 0.07 (Lac/Cho) 
5X: 1.03 ± 0.30 
1.57 ±  0.29 (Tumor) 
0.47 ± 0.24 (Lac/Cho) 
 
 
 
 
4 
 
 
 
F 
 
 
 
 
5 
 
 
 
neurofibromatosis 
1 and astrocytoma 
 
1X: 1.36 ± 0.71 
0.55 ± 0.38 (Lac/Cr) 
2X: 1.32 ± 0.56 
0.51 ± 0.35 (Lac/Cr) 
3X: 1.32 ± 0.55 
0.52 ± 0.41 (Lac/Cr) 
4X: 1.35 ± 0.58 
0.52 ± 0.43 (Lac/Cr) 
5X: 1.27 ± 0.62 
0.52 ± 0.47 (Lac/Cr) 
 
1X: 1.29 ± 0.79 
0.44 ± 0.26 (Lac/NAA) 
2X: 1.19 ± 0.57 
0.39 ± 0.18 (Lac/NAA) 
3X: 1.18 ± 0.52 
0.38 ± 0.17 (Lac/NAA) 
4X: 1.16 ± 0.52 
0.39 ± 0.28 (Lac/NAA) 
5X: 1.10 ± 0.50 
0.37 ± 0.28 (Lac/NAA) 
 
1X: 1.33 ± 0.30 
0.43 ± 0.34 (Lac/Cho) 
2X: 1.32 ± 0.28 
0.40 ± 0.29 (Lac/Cho) 
3X: 1.32 ± 0.27 
0.37 ± 0.17 (Lac/Cho) 
4X: 1.30 ± 0.27 
0.40 ± 0.29 (Lac/Cho) 
5X: 1.25 ± 0.21 
0.39 ± 0.25 (Lac/Cho) 
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 Case Gender 
 
Age 
(years) 
 
Reason for MRI NAA/Cr 
(Mean ± SD) 
Cho/NAA 
(Mean ± SD) 
Cho/Cr 
(Mean ± SD) 
 
 
 
5 
 
 
 
F 
 
 
 
 
10 
 
 
 
left optic nerve 
glioma 
 
1X: 1.56 ±1.73 
2X: 1.42 ± 1.23 
3X: 1.35 ± 0.70 
4X: 1.45 ± 0.94 
5X: 1.38 ± 0.62 
 
 
 
1X: 0.66 ± 0.58 
2X: 0.73 ± 0.67 
3X: 0.77 ± 0.79 
4X: 0.74 ± 0.85 
5X: 0.76 ± 1.06 
 
 
1X: 0.70 ± 0.18 
2X: 0.70 ± 0.20 
3X: 0.69 ± 0.19 
4X: 0.67 ± 0.18 
5X: 0.68 ± 0.14 
 
 
 
 
6 
 
 
 
M 
 
 
 
 
 
3 
 
 
 
grade 2 
astrocytoma 
 
1X: 2.18 ± 1.49 
2X: 2.31 ± 1.95 
3X: 2.19 ± 1.55 
4X: 2.16 ± 1.54 
5X: 2.18 ± 1.52 
 
 
1X: 0.49 ± 0.18 
2X: 0.48 ± 0.20 
3X: 0.50 ± 0.25 
4X: 0.51 ± 0.23 
5X: 0.50 ± 0.24 
 
 
1X: 0.86 ± 0.17 
2X: 0.84 ± 0.17 
3X: 0.83 ± 0.16 
4X: 0.84 ± 0.20 
5X: 0.82 ± 0.17 
 
 
 
 
 
 
 
1
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